

CPC COOPERATIVE PATENT CLASSIFICATION

C CHEMISTRY; METALLURGY

(NOTES omitted)

CHEMISTRY

C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing microorganisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from microorganisms or animal material [A01N 63/00](#); food compositions [A21](#), [A23](#); medicinal preparations [A61K](#); chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles [A61L](#); fertilisers [C05](#)); **PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS** (preservation of living parts of humans or animals [A01N 1/02](#)); **MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA** (microbiological testing media [C12Q](#))

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

WARNING

The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

| | | |
|--|------------|--|
| C12N 1/11 | covered by | C12N 15/79 |
| C12N 1/13 | covered by | C12N 15/79 |
| C12N 1/15 | covered by | C12N 15/80 |
| C12N 1/19 | covered by | C12N 15/81 |
| C12N 1/21 | covered by | C12N 15/74 |
| C12N 5/02 | covered by | C12N 5/00 , C12N 5/04 - C12N 5/166 |
| C12N 5/07 - C12N 5/095 | covered by | C12N 5/06 and subgroups |
| C12N 5/18 - C12N 5/28 | covered by | C12N 5/16 and subgroups |
| C12N 5/18 | covered by | C12N 5/16 |
| C12N 5/20 | covered by | C12N 5/163 |
| C12N 5/22 | covered by | C12N 5/16 |
| C12N 5/24 | covered by | C12N 5/163 |
| C12N 5/26 | covered by | C12N 5/166 |
| C12N 5/28 | covered by | C12N 5/166 |
| C12N 7/01 | covered by | C12N 7/00 |
| C12N 9/02 - C12N 9/08 | covered by | |
| C12N 9/26 | covered by | C12N 9/2408 |
| C12N 9/28 - C12N 9/30 | covered by | |
| C12N 9/32 | covered by | |
| C12N 9/34 | covered by | |
| C12N 9/36 | covered by | |
| C12N 9/38 | covered by | C12N 9/2468 |
| C12N 9/40 | covered by | |
| C12N 9/42 | covered by | C12N 9/2434 |
| C12N 9/44 | covered by | C12N 9/2451 |
| C12N 9/46 | covered by | |
| C12N 9/56 | covered by | |
| C12N 9/66 | covered by | |
| C12N 9/68 | covered by | |

C12N

C12N

(continued)

| | | |
|------------|------------|--|
| C12N 9/70 | covered by | C07K 14/3153 |
| C12N 9/72 | covered by | |
| C12N 9/74 | covered by | |
| C12N 9/76 | covered by | |
| C12N 15/05 | covered by | C12N 5/14 |
| C12N 15/06 | covered by | C12N 5/16 |
| C12N 15/07 | covered by | C12N 5/16 |
| C12N 15/08 | covered by | C12N 5/166 |
| C12N 15/12 | covered by | C07K 14/435 |
| C12N 15/13 | covered by | C07K 16/00 |
| C12N 15/14 | covered by | C07K 14/765 |
| C12N 15/15 | covered by | C07K 14/81 |
| C12N 15/16 | covered by | C07K 14/575 |
| C12N 15/17 | covered by | C07K 14/62 |
| C12N 15/18 | covered by | C07K 14/61 |
| C12N 15/19 | covered by | C07K 14/52 |
| C12N 15/20 | covered by | C07K 14/555 |
| C12N 15/21 | covered by | C07K 14/56 |
| C12N 15/22 | covered by | C07K 14/565 |
| C12N 15/23 | covered by | C07K 14/57 |
| C12N 15/24 | covered by | C07K 14/54 |
| C12N 15/25 | covered by | C07K 14/545 |
| C12N 15/26 | covered by | C07K 14/55 |
| C12N 15/27 | covered by | C07K 14/53 |
| C12N 15/28 | covered by | C07K 14/525 |
| C12N 15/29 | covered by | C07K 14/415 |
| C12N 15/30 | covered by | C07K 14/44 |
| C12N 15/31 | covered by | C07K 14/195 , C07K 14/005 |
| C12N 15/32 | covered by | C07K 14/325 |
| C12N 15/33 | covered by | C07K 14/005 |
| C12N 15/34 | covered by | C07K 14/01 |
| C12N 15/35 | covered by | C07K 14/015 |
| C12N 15/36 | covered by | C07K 14/02 |
| C12N 15/37 | covered by | C07K 14/025 |
| C12N 15/38 | covered by | C07K 14/03 |
| C12N 15/39 | covered by | C07K 14/065 |
| C12N 15/40 | covered by | C07K 14/08 |
| C12N 15/41 | covered by | C07K 14/085 |
| C12N 15/42 | covered by | C07K 14/09 |
| C12N 15/43 | covered by | C07K 14/105 |
| C12N 15/44 | covered by | C07K 14/11 |
| C12N 15/45 | covered by | C07K 14/115 |
| C12N 15/46 | covered by | C07K 14/14 |
| C12N 15/47 | covered by | C07K 14/145 |
| C12N 15/48 | covered by | C07K 14/15 |
| C12N 15/49 | covered by | C07K 14/155 |
| C12N 15/50 | covered by | C07K 14/165 |
| C12N 15/51 | covered by | C07K 14/02 , C07K 14/10 , C07K 14/18 |
| C12N 15/53 | covered by | C12N9/02 |
| C12N 15/54 | covered by | C12N 9/10 |
| C12N 15/55 | covered by | C12N 9/14 |
| C12N 15/56 | covered by | C12N 9/24 |
| C12N 15/57 | covered by | C12N 9/48 |
| C12N 15/58 | covered by | C12N 9/6456 |
| C12N 15/59 | covered by | C12N 9/6483 |
| C12N 15/60 | covered by | C12N 9/88 |
| C12N 15/61 | covered by | C12N 9/90 |
| C12N 15/83 | covered by | C12N 15/82 |
| C12N 15/84 | covered by | C12N 15/82 |

| | | | |
|-------------|--|--------|--|
| 1/00 | Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from microorganisms A61K 35/66; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor | | three somatic lineages (ectoderm, mesoderm, endoderm); |
| 1/005 | • {after treatment of microbial biomass not covered by C12N 1/02 - C12N 1/08 } | | • a "multipotent" cell is restricted to one lineage; |
| 1/02 | • Separating microorganisms from their culture media | 5/0006 | • "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny. |
| 1/04 | • Preserving or maintaining viable microorganisms (immobilised microorganisms C12N 11/00) | 5/0012 | • {Modification of the membrane of cells, e.g. cell decoration} |
| 1/06 | • Lysis of microorganisms | 5/0018 | • {Cell encapsulation} |
| 1/063 | • . . {of yeast} | 5/0018 | • {Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06)} |
| 1/066 | • . . {by physical methods} | 5/0025 | • . . {Culture media for plant cell or plant tissue culture} |
| 1/08 | • Reducing the nucleic acid content | 5/0031 | • . . {Serum-free culture media} |
| 1/10 | • Protozoa; Culture media therefor | | <u>WARNING</u> |
| 1/12 | • Unicellular algae; Culture media therefor (culture of multi-cellular plants A01G ; as new plants A01H 13/00) | | This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to C12N 5/0037 - C12N 5/0056 |
| 1/14 | • Fungi (culture of mushrooms A01G 1/04 ; as new plants per se A01H 15/00 ; {fungi per se C12R 1/645 - C12R 1/885 }) Culture media therefor | | |
| 1/16 | • . . Yeasts; Culture media therefor | 5/0037 | • . . {Serum-free medium, which may still contain naturally-sourced components} |
| 1/18 | • . . . Baker's yeast; Brewer's yeast | 5/0043 | • . . {Medium free of human- or animal-derived components} |
| 1/20 | • Bacteria {(bacteria per se C12R 1/01 - C12R 1/64)}; Culture media therefor | 5/005 | • . . {Protein-free medium} |
| 1/22 | • Processes using, or culture media containing, cellulose or hydrolysates thereof | 5/0056 | • . . {Xeno-free medium} |
| 1/24 | • Processes using, or culture media containing, waste sulfite liquor | 5/0062 | • {General methods for three-dimensional culture} |
| 1/26 | • Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms C10G 32/00) | 5/0068 | • {General culture methods using substrates (for specific animal cell type C12N 5/06)} |
| 1/28 | • . . aliphatic | 5/0075 | • . . {using microcarriers} |
| 1/30 | • . . . having five or less carbon atoms | 5/0081 | • {Purging biological preparations of unwanted cells} |
| 1/32 | • Processes using, or culture media containing, lower alkanols, i.e. C ₁ to C ₆ | 5/0087 | • . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells} |
| 1/34 | • Processes using foam culture | 5/0093 | • . . {Purging against cancer cells} |
| 1/36 | • Adaptation or attenuation of cells | 5/04 | • Plant cells or tissues {(culture media C12N 5/0025)} |
| 1/38 | • Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence) | 5/06 | • {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues A01N 1/02); Not used, see subgroups} |
| 3/00 | Spore forming or isolating processes | | <u>NOTE</u> |
| 5/00 | Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00) | | In this group, the following words are used with the meanings indicated: |
| | <u>NOTE</u> | | • a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta; |
| | In this group, the following words are used with the meanings indicated: | | • a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm); |
| | • a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta; | | • a "multipotent" cell is restricted to one lineage. |
| | • a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the | | "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells |

| | | | |
|--------|--|---|--|
| 5/0601 | . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor} | 5/0634 | . . . {Cells from the blood or the immune system} |
| 5/0602 | . . {Vertebrate cells} | NOTE | |
| | NOTE | Committed progenitors are classified with their progeny | |
| | Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for | 5/0635 | {B lymphocytes} |
| 5/0603 | . . . {Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies} | 5/0636 | {T lymphocytes} |
| 5/0604 | {Whole embryos; Culture medium therefor} | 5/0637 | {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)} |
| 5/0605 | {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly} | 5/0638 | {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]} |
| 5/0606 | {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N 5/0611 , induced pluripotent stem cells C12N 5/0696)} | 5/0639 | {Dendritic cells, e.g. Langerhans cells in the epidermis} |
| 5/0607 | . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)} | 5/064 | {Immunosuppressive dendritic cells} |
| 5/0608 | . . . {Germ cells (production of embryos, nuclear transfer A01K 67/027); Not used, see subgroups} | 5/0641 | {Erythrocytes} |
| 5/0609 | {Oocytes, oögonia (fertilised oocytes C12N 5/0604)} | 5/0642 | {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells} |
| 5/061 | {Sperm cells, spermatogonia} | 5/0643 | {Osteoclasts} |
| 5/0611 | {Primordial germ cells, e.g. embryonic germ cells [EG]} | 5/0644 | {Platelets; Megakaryocytes} |
| 5/0612 | {sorting of gametes, e.g. according to sex or motility} | 5/0645 | {Macrophages, e.g. Kuepfer cells in the liver; Monocytes} |
| 5/0613 | . . . {Cells from endocrine organs (pancreas C12N 5/0676 , gonads C12N 5/0681)} | 5/0646 | {Natural killers cells [NK], NKT cells} |
| 5/0614 | {Adrenal gland} | 5/0647 | {Haematopoietic stem cells; Uncommitted or multipotent progenitors} |
| 5/0615 | {Pineal gland} | 5/0648 | {Splenocytes} |
| 5/0616 | {Pituitary gland} | 5/065 | {Thymocytes} |
| 5/0617 | {Thyroid and parathyroid glands} | 5/0651 | {Lymph nodes} |
| 5/0618 | . . . {Cells of the nervous system} | 5/0652 | . . . {Cells of skeletal and connective tissues; Mesenchyme} |
| 5/0619 | {Neurons} | 5/0653 | {Adipocytes; Adipose tissue} |
| 5/062 | {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain} | 5/0654 | {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth} |
| 5/0621 | {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)} | 5/0655 | {Chondrocytes; Cartilage} |
| 5/0622 | {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells} | 5/0656 | {Adult fibroblasts} |
| 5/0623 | {Stem cells} | 5/0657 | {Cardiomyocytes; Heart cells} |
| 5/0625 | . . . {Epidermal cells, skin cells; Cells of the oral mucosa} | 5/0658 | {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts} |
| 5/0626 | {Melanocytes} | 5/0659 | {Satellite cells} |
| 5/0627 | {Hair cells} | 5/066 | {Tenocytes; Tendons, Ligaments} |
| 5/0628 | {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)} | 5/0661 | {Smooth muscle cells} |
| 5/0629 | {Keratinocytes; Whole skin} | 5/0662 | {Stem cells} |
| 5/063 | {Keratinocyte stem cells; Keratinocyte progenitors} | 5/0663 | {Bone marrow mesenchymal stem cells (BM-MSC)} |
| 5/0631 | {Mammary cells} | 5/0664 | {Dental pulp stem cells, Dental follicle stem cells} |
| 5/0632 | {Cells of the oral mucosa} | 5/0665 | {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood} |
| 5/0633 | {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands} | 5/0666 | {Mesenchymal stem cells from hair follicles} |
| | | 5/0667 | {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells} |
| | | 5/0668 | {Mesenchymal stem cells from other natural sources} |
| | | 5/0669 | {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)} |
| | | 5/067 | . . . {Hepatocytes} |
| | | 5/0671 | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} |
| | | 5/0672 | {Stem cells; Progenitor cells; Precursor cells; Oval cells} |
| | | 5/0676 | . . . {Pancreatic cells} |

| | | | |
|-------------|--|-------------|---|
| 5/0677 | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} | 7/045 | . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered} |
| 5/0678 | {Stem cells; Progenitor cells; Precursor cells} | 7/06 | . . {Inactivation or attenuation} by chemical treatment |
| 5/0679 | . . . {Cells of the gastro-intestinal tract} | 7/08 | . . {Inactivation or attenuation} by serial passage of virus |
| 5/068 | {Stem cells; Progenitors} | | |
| 5/0681 | . . . {Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups} | 9/00 | Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66 , A61Q 11/00 ; medicinal preparations containing enzymes or proenzymes A61K 38/43 ; enzyme containing detergent compositions C11D ; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113 }); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00) |
| 5/0682 | {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)} | | NOTE |
| 5/0683 | {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)} | | Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis. |
| 5/0684 | . . . {Cells of the urinary tract or kidneys} | 9/0002 | . {Antibodies with enzymatic activity, e.g. abzymes} |
| 5/0685 | {Bladder epithelial cells} | 9/0004 | . {Oxidoreductases (1.)} |
| 5/0686 | {Kidney cells} | 9/0006 | . . {acting on CH-OH groups as donors (1.1)} |
| 5/0687 | {Renal stem cells; Renal progenitors} | 9/0008 | . . {acting on the aldehyde or oxo group of donors (1.2)} |
| 5/0688 | . . . {Cells from the lungs or the respiratory tract} | 9/001 | . . {acting on the CH-CH group of donors (1.3)} |
| 5/0689 | {Stem cells; Progenitors} | 9/0012 | . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)} |
| 5/069 | . . . {Vascular Endothelial cells} | 9/0014 | . . . {acting on the CH-NH ₂ group of donors (1.4)} |
| 5/0691 | {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels} | 9/0016 | {with NAD or NADP as acceptor (1.4.1)} |
| 5/0692 | {Stem cells; Progenitor cells; Precursor cells} | 9/0018 | {Phenylalanine dehydrogenase (1.4.1.20)} |
| 5/0693 | . . . {Tumour cells; Cancer cells} | 9/002 | {with a cytochrome as acceptor (1.4.2)} |
| 5/0694 | {Cells of blood, e.g. leukemia cells, myeloma cells} | 9/0022 | {with oxygen as acceptor (1.4.3)} |
| 5/0695 | {Stem cells; Progenitor cells; Precursor cells} | 9/0024 | {D-Amino acid oxidase (1.4.3.3)} |
| 5/0696 | . . . {Artificially induced pluripotent stem cells, e.g. iPS} | 9/0026 | . . . {acting on CH-NH groups of donors (1.5)} |
| 5/0697 | . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)} | 9/0028 | {with NAD or NADP as acceptor (1.5.1)} |
| 5/0698 | . . . {Skin equivalents} | 9/003 | {Dihydrofolate reductase [DHFR] (1.5.1.3)} |
| 5/10 | . Cells modified by introduction of foreign genetic material {Not used, see subgroups} | 9/0032 | {with oxygen as acceptor (1.5.3)} |
| 5/12 | . . Fused cells, e.g. hybridomas | 9/0034 | {Sarcosine oxidase (1.5.3.1)} |
| 5/14 | . . . Plant cells | 9/0036 | . . . {acting on NADH or NADPH (1.6)} |
| 5/16 | . . . Animal cells | 9/0038 | {with a heme protein as acceptor (1.6.2)} |
| 5/163 | {one of the fusion partners being a B or a T lymphocyte} | 9/004 | {Cytochrome-b5 reductase (1.6.2.2)} |
| 5/166 | {resulting from interspecies fusion} | 9/0042 | {NADPH-cytochrome P450 reductase (1.6.2.4)} |
| 7/00 | Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00) | 9/0044 | . . . {acting on other nitrogen compounds as donors (1.7)} |
| | WARNING | 9/0046 | {with oxygen as acceptor (1.7.3)} |
| | From March 15, 2012 groups C12N 7/02 - C12N 7/08 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00 . | 9/0048 | {Uricase (1.7.3.3)} |
| 7/02 | . Recovery or purification | 9/0051 | . . {acting on a sulfur group of donors (1.8)} |
| 7/025 | . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus} | 9/0053 | . . {acting on a heme group of donors (1.9)} |
| 7/04 | . Inactivation or attenuation; Producing viral sub-units | 9/0055 | . . {acting on diphenols and related substances as donors (1.10)} |
| | | 9/0057 | . . . {with oxygen as acceptor (1.10.3)} |
| | | 9/0059 | {Catechol oxidase (1.10.3.1), i.e. tyrosinase} |
| | | 9/0061 | {Laccase (1.10.3.2)} |
| | | 9/0063 | {Ascorbate oxidase (1.10.3.3)} |
| | | 9/0065 | . . {acting on hydrogen peroxide as acceptor (1.11)} |
| | | 9/0067 | . . {acting on hydrogen as donor (1.12)} |

- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 {Nitric-oxide synthase (1.14.13.39)}
- 9/0077 . . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
- 9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
- 9/0081 {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
- 9/0083 . . . {Miscellaneous (1.14.99)}
- 9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
- 9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
- 9/0089 . . {acting on superoxide as acceptor (1.15)}
- 9/0091 . . {oxidizing metal ions (1.16)}
- 9/0093 . . {acting on CH or CH₂ groups (1.17)}
- 9/0095 . . {acting on iron-sulfur proteins as donor (1.18)}
- 9/0097 . . {acting on reduced flavodoxin as donor (1.19)}
- 9/10 . Transferases (2.) ([ribonucleases C12N 9/22](#))
- 9/1003 . . {transferring one-carbon groups (2.1)}
- 9/1007 . . . {Methyltransferases (general) (2.1.1.)}
- 9/1011 {Catechol O-methyltransferase (2.1.1.6)}
- 9/1014 . . . {Hydroxymethyl-, formyl-transferases (2.1.2)}
- 9/1018 . . . {Carboxy- and carbamoyl transferases (2.1.3)}
- 9/1022 . . {transferring aldehyde or ketonic groups (2.2)}
- 9/1025 . . {Acyltransferases (2.3)}
- 9/1029 . . . {transferring groups other than amino-acyl groups (2.3.1)}
- 9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
- 9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
- 9/104 . . . {Aminoacyltransferases (2.3.2)}
- 9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
- 9/1048 . . {Glycosyltransferases (2.4)}
- 9/1051 . . . {Hexosyltransferases (2.4.1)}
- 9/1055 {Levansucrase (2.4.1.10)}
- 9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}
- 9/1062 {Sucrose synthase (2.4.1.13)}
- 9/1066 {Sucrose phosphate synthase (2.4.1.14)}
- 9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}
- 9/1074 {Cyclomaltodextrin glucanotransferase (2.4.1.19)}
- 9/1077 . . . {Pentosyltransferases (2.4.2)}
- 9/1081 . . . {transferring other glycosyl groups (2.4.99)}
- 9/1085 . . {transferring alkyl or aryl groups other than methyl groups (2.5)}
- 9/1088 . . . {Glutathione transferase (2.5.1.18)}
- 9/1092 . . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}
- 9/1096 . . {transferring nitrogenous groups (2.6)}
- 9/12 . . transferring phosphorus containing groups, e.g. kinases (2.7)
- 9/1205 . . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- 9/1211 {Thymidine kinase (2.7.1.21)}
- 9/1217 . . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}
- 9/1223 . . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}
- 9/1229 . . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}
- 9/1235 . . . {Diphosphotransferases (2.7.6)}
- 9/1241 . . . {Nucleotidyltransferases (2.7.7)}
- 9/1247 {DNA-directed RNA polymerase (2.7.7.6)}
- 9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- 9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}
- 9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}
- 9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}
- 9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- 9/1282 {RNA uridylyltransferase (2.7.7.52)}
- 9/1288 . . . {Transferases for other substituted phosphate groups (2.7.8)}
- 9/1294 . . . {Phosphotransferases with paired acceptors (2.7.9)}
- 9/13 . . {transferring sulfur containing groups (2.8)}
- 9/14 . Hydrolases (3)
- 9/16 . . acting on ester bonds (3.1)
- 9/18 . . . Carboxylic ester hydrolases {(3.1.1)}
- 9/20 Triglyceride splitting, e.g. by means of lipase
- 9/22 . . . Ribonucleases {RNases, DNases ([catalytic nucleic acids C12N 15/113](#))}
- 9/24 . . acting on glycosyl compounds (3.2)
- 9/2402 . . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- 9/2405 {Glucanases}
- 9/2408 {acting on alpha -1,4-glucosidic bonds}
- 9/2411 {Amylases}
- 9/2414 {Alpha-amylase (3.2.1.1.)}
- 9/2417 {from microbiological source}
- 9/242 {Fungal source}
- 9/2422 {from plant source}
- 9/2425 {Beta-amylase (3.2.1.2)}
- 9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
- 9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
- 9/2434 {acting on beta-1,4-glucosidic bonds}
- 9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
- 9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
- 9/2442 {Chitinase (3.2.1.14)}
- 9/2445 {Beta-glucosidase (3.2.1.21)}
- 9/2448 {Licheninase (3.2.1.73)}
- 9/2451 {acting on alpha-1,6-glucosidic bonds}
- 9/2454 {Dextranase (3.2.1.11)}
- 9/2457 {Pullulanase (3.2.1.41)}
- 9/246 {Isoamylase (3.2.1.68)}
- 9/2462 {Lysozyme (3.2.1.17)}
- 9/2465 {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}

| | | | |
|--|---|--------|---|
| 9/2468 | {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)} | 9/6427 | {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)} |
| 9/2471 | {Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase} | 9/6429 | {Thrombin (3.4.21.5)} |
| 9/2474 | {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase} | 9/6432 | {Coagulation factor Xa (3.4.21.6)} |
| 9/2477 | {Hemicellulases not provided in a preceding group} | 9/6435 | {Plasmin (3.4.21.7), i.e. fibrinolysin} |
| 9/248 | {Xylanases} | 9/6437 | {Coagulation factor VIIa (3.4.21.21)} |
| 9/2482 | {Endo-1,4-beta-xylanase (3.2.1.8)} | 9/644 | {Coagulation factor IXa (3.4.21.22)} |
| 9/2485 | {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase} | 9/6443 | {Coagulation factor XIa (3.4.21.27)} |
| 9/2488 | {Mannanases} | 9/6445 | {Kallikreins (3.4.21.34; 3.4.21.35)} |
| 9/2491 | {Beta-mannosidase (3.2.1.25), i.e. mannanase} | 9/6448 | {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)} |
| 9/2494 | {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase} | 9/6451 | {Coagulation factor XIIa (3.4.21.38)} |
| 9/2497 | . . . {hydrolysing N- glycosyl compounds (3.2.2)} | 9/6454 | {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases} |
| 9/48 | . . acting on peptide bonds (3.4) | 9/6456 | {Plasminogen activators} |
| 9/485 | . . . {Exopeptidases (3.4.11-3.4.19)} | 9/6459 | {t-plasminogen activator (3.4.21.68), i.e. tPA} |
| 9/50 | . . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)} | 9/6462 | {u-Plasminogen activator (3.4.21.73), i.e. urokinase} |
| WARNING | | 9/6464 | {Protein C (3.4.21.69)} |
| Group C12N 9/50 is impacted by reclassification into group C12N 9/52 . | | 9/6467 | {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)} |
| Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search. | | 9/647 | {Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups} |
| 9/503 | {derived from viruses} | 9/6472 | {Cysteine endopeptidases (3.4.22)} |
| 9/506 | {derived from RNA viruses} | 9/6475 | {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)} |
| 9/52 | derived from bacteria {or Archaea} | 9/6478 | {Aspartic endopeptidases (3.4.23)} |
| NOTE | | 9/6481 | {Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)} |
| {In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.} | | 9/6483 | {Chymosin (3.4.23.4), i.e. rennin} |
| WARNING | | 9/6486 | {Renin (3.4.23.15)} |
| Group C12N 9/52 is incomplete pending reclassification of documents from group C12N 9/50 . | | 9/6489 | {Metalloendopeptidases (3.4.24)} |
| Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search. | | 9/6491 | {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)} |
| 9/54 | bacteria being Bacillus | 9/6494 | {Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11} |
| 9/58 | derived from fungi | 9/6497 | {Endothelin-converting enzyme (3.4.24.71)} |
| 9/60 | from yeast | 9/78 | . . acting on carbon to nitrogen bonds other than peptide bonds (3.5) |
| 9/62 | from Aspergillus | 9/80 | . . . acting on amide bonds in linear amides {(3.5.1)} |
| 9/63 | {derived from plants} | 9/82 | Asparaginase {(3.5.1.1)} |
| 9/64 | derived from animal tissue | 9/84 | Penicillin amidase {(3.5.1.11)} |
| 9/6402 | {from non-mammals} | 9/86 | . . . acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)} |
| 9/6405 | {not being snakes} | 9/88 | . Lyases (4.) |
| 9/6408 | {Serine endopeptidases (3.4.21)} | 9/90 | . Isomerases (5.) |
| 9/641 | {Cysteine endopeptidases (3.4.22)} | 9/92 | . . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)} |
| 9/6413 | {Aspartic endopeptidases (3.4.23)} | 9/93 | . {Ligases (6)} |
| 9/6416 | {Metalloendopeptidases (3.4.24)} | 9/94 | . Pancreatin |
| 9/6418 | {from snakes} | 9/96 | . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates |
| 9/6421 | {from mammals} | | |
| 9/6424 | {Serine endopeptidases (3.4.21)} | | |

- 9/98 . Preparation of granular or free-flowing enzyme compositions ([C12N 9/96](#) takes precedence)
- 9/99 . Enzyme inactivation by chemical treatment
- 11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof**
- 11/02 . Enzymes or microbial cells being immobilised on or in an organic carrier
- 11/04 . . entrapped within the carrier, e.g. gel, hollow fibre
- 11/06 . . attached to the carrier via a bridging agent
- 11/08 . . carrier being a synthetic polymer
- 11/10 . . carrier being a carbohydrate
- 11/12 . . . Cellulose or derivatives thereof
- 11/14 . Enzymes or microbial cells being immobilised on or in an inorganic carrier
- 11/16 . Enzymes or microbial cells being immobilised on or in a biological cell
- 11/18 . Multi-enzyme systems
- 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves**
- 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se [C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se [A01H](#); plant reproduction by tissue culture techniques [A01H 4/00](#); new animals per se [A01K 67/00](#); use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy [A61K 48/00](#))**
- 15/01 . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- 15/02 . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies [C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- 15/03 . . Bacteria
- 15/04 . . Fungi
- 15/09 . Recombinant DNA-technology
- 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA [C07H 21/00](#); preparation of non-structural polynucleotides from microorganisms or with enzymes [C12P 19/34](#))
- NOTE**
- After the symbol [C12N 15/10](#) - [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 {by using magnetic beads}
- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays [C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}

- 15/1093 . . . {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.
- 15/62 . . . DNA sequences coding for fusion proteins
- NOTE**
- In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.
- 15/625 {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- 15/65 . . . using markers ([enzymes used as markers C12N 15/52](#))
- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- NOTE**
- In this group, the following expression is used with the meaning indicated:
- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.
- 15/67 . . . General methods for enhancing the expression
- 15/68 Stabilisation of the vector
- 15/69 Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli
- NOTES**
1. This group covers the use of E. coli as host.
 2. Shuttle vectors also replicating in E. coli are classified according to the other host.
- 15/71 Expression systems using regulatory sequences derived from the trp-operon
- 15/72 Expression systems using regulatory sequences derived from the lac-operon
- 15/73 Expression systems using phage (lambda) regulatory sequences
- 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- NOTE**
- This group covers the use of prokaryotes as hosts.

| | | | |
|---|--|---------|---|
| 15/743 | {for Agrobacterium; Rhizobium; Bradyrhizobium} | 15/8216 | {Methods for controlling, regulating or enhancing expression of transgenes in plant cells} |
| 15/746 | {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)} | 15/8217 | {Gene switch} |
| 15/75 | for Bacillus | 15/8218 | {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]} |
| 15/76 | for Actinomyces; for Streptomyces | 15/822 | {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression} |
| 15/77 | for Corynebacterium; for Brevibacterium | 15/8221 | {Transit peptides} |
| 15/78 | for Pseudomonas | 15/8222 | {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation} |
| 15/79 | . . . Vectors or expression systems specially adapted for eukaryotic hosts | 15/8223 | {Vegetative tissue-specific promoters} |
| NOTE | | 15/8225 | {Leaf-specific, e.g. including petioles, stomata} |
| This group <u>covers</u> the use of eukaryotes as hosts. | | 15/8226 | {Stem-specific, e.g. including tubers, beets} |
| 15/80 | for fungi | 15/8227 | {Root-specific} |
| 15/81 | for yeasts | 15/8229 | {Meristem-specific, e.g. nodal, apical} |
| 15/815 | {for yeasts other than Saccharomyces} | 15/823 | {Reproductive tissue-specific promoters} |
| 15/82 | for plant cells {, e.g. plant artificial chromosomes (PACs)} | 15/8231 | {Male-specific, e.g. anther, tapetum, pollen} |
| WARNING | | 15/8233 | {Female-specific, e.g. pistil, ovule} |
| Documents are being continuously reclassified into this new classification scheme. See Warning notes below | | 15/8234 | {Seed-specific, e.g. embryo, endosperm} |
| 15/8201 | {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation} | 15/8235 | {Fruit-specific} |
| 15/8202 | {by biological means, e.g. cell mediated or natural vector} | 15/8237 | {Externally regulated expression systems} |
| 15/8203 | {Virus mediated transformation} | 15/8238 | {chemically inducible, e.g. tetracycline} |
| 15/8205 | {Agrobacterium mediated transformation} | 15/8239 | {pathogen inducible} |
| 15/8206 | {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated} | 15/8241 | {Phenotypically and genetically modified plants via recombinant DNA technology} |
| 15/8207 | {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers} | 15/8242 | {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits} |
| 15/8209 | {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers} | 15/8243 | {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine} |
| NOTE | | 15/8245 | {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis} |
| Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209 | | 15/8246 | {Non-starch polysaccharides, e.g. cellulose, fructans, levans} |
| 15/821 | {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers} | 15/8247 | {involving modified lipid metabolism, e.g. seed oil composition} |
| 15/8212 | {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid} | 15/8249 | {involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life} |
| 15/8213 | {Targeted insertion of genes into the plant genome by homologous recombination} | | |
| 15/8214 | {Plastid transformation} | | |

15/825 {involving pigment biosynthesis}

NOTE

Transgenic plants with altered flower morphology are also classified in this group

15/8251 {Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}

15/8253 {Methionine or cysteine}

15/8254 {Tryptophan or lysine}

15/8255 {involving lignin biosynthesis}

15/8257 {for the production of primary gene products, e.g. pharmaceutical products, interferon}

15/8258 {for the production of oral vaccines (antigens) or immunoglobulins}

15/8259 {Phytoremediation}

15/8261 {with agronomic (input) traits, e.g. crop yield}

15/8262 {involving plant development (not used)}

15/8263 {Ablation; Apoptosis}

15/8265 {Transgene containment, e.g. gene dispersal}

15/8266 {Abscission; Dehiscence; Senescence}

15/8267 {Seed dormancy, germination or sprouting}

15/8269 {Photosynthesis}

15/827 {Flower development or morphology, e.g. flowering promoting factor [FPF]}

15/8271 {for stress resistance, e.g. heavy metal resistance}

15/8273 {for drought, cold, salt resistance}

15/8274 {for herbicide resistance}

15/8275 {Glyphosate}

15/8277 {Phosphinotricin}

15/8278 {Sulfonylurea}

15/8279 {for biotic stress resistance, pathogen resistance, disease resistance}

15/8281 {for bacterial resistance}

15/8282 {for fungal resistance}

15/8283 {for virus resistance}

15/8285 {for nematode resistance}

15/8286 {for insect resistance}

15/8287 {for fertility modification, e.g. apomixis}

15/8289 {Male sterility}

15/829 {Female sterility}

15/8291 {Hormone-influenced development}

15/8293 {Absciscic acid [ABA]}

15/8294 {Auxins}

15/8295 {Cytokinins}

15/8297 {Gibberellins; GA3}

15/8298 {Brassinosteroids}

15/85 for animal cells

15/8509 {for producing genetically modified animals, e.g. transgenic}

NOTE

Additional aspects of the modified animals are classified in the groups [A01K 2207/00](#) - [A01K 2267/00](#)

2015/8518 {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}

2015/8527 {for producing animal models, e.g. for tests or diseases}

2015/8536 {Animal models for genetic diseases}

2015/8545 {for Alzheimer's disease}

2015/8554 {Invertebrates models for Alzheimer's disease}

2015/8563 {for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}

2015/8572 {Animal models for proliferative diseases, e.g. comprising an oncogene}

2015/8581 {Animal models for infectious diseases, e.g. AIDS}

2015/859 {Animal models comprising reporter system for screening tests}

15/86 Viral vectors

WARNING

From March 15, 2012 groups [C12N 15/861](#) - [C12N 15/869](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00](#)-[C12N 2795/00](#)

15/861 Adenoviral vectors

15/8613 {Chimaeric vector systems comprising heterologous sequences for production of another viral vector}

15/8616 {Special methods for targeting systems}

15/863 Poxviral vectors, {e.g. entomopoxvirus}

15/8633 {Avian poxviral vectors}

15/8636 {Vaccina virus vectors}

15/864 Parvoviral vectors {, e.g. parvovirus, densovirus}

15/8645 {Adeno-associated virus}

15/866 Baculoviral vectors

15/867 Retroviral vectors

15/8673 {Special methods for packaging systems}

15/8676 {Special methods for targeting systems}

15/869 Herpesviral vectors

15/8695 {Herpes simplex virus-based vectors}

15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

| | | | |
|-----------|---|-----------|--|
| 15/873 | . . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos | 2310/3125 | Methylphosphonates |
| 15/877 | Techniques for producing new mammalian cloned embryos | 2310/313 | . . . Phosphorodithioates |
| 15/8771 | {Bovine embryos} | 2310/314 | . . . Phosphoramidates |
| 15/8772 | {Caprine embryos} | 2310/3145 | with the nitrogen in 3' or 5'-position |
| 15/8773 | {Ovine embryos} | 2310/315 | . . . Phosphorothioates |
| 15/8775 | {Murine embryos} | 2310/316 | . . . Phosphonothioates |
| 15/8776 | {Primate embryos} | 2310/317 | . . . with an inverted bond, e.g. a cap structure |
| 15/8777 | {Rabbit embryos} | 2310/318 | . . . where the PO2 is completely replaced, e.g. MMI or formacetal |
| 15/8778 | {Swine embryos} | 2310/3181 | Peptide nucleic acid, PNA |
| 15/88 | . . . using microencapsulation, e.g. using {amphiphile} liposome vesicle | 2310/3183 | Diol linkers, e.g. glycols or propanediols |
| 15/89 | . . . using microinjection | 2310/319 | . . . linked by 2'-5' linkages, i.e. having a free 3'-position |
| 15/895 | {using biolistic methods} | 2310/32 | . . of the sugar |
| 15/90 | . . . Stable introduction of foreign DNA into chromosome | 2310/321 | . . . 2'-O-R Modification |
| 15/902 | {using homologous recombination} | 2310/322 | . . . 2'-R Modification |
| 15/905 | {in yeast} | 2310/323 | . . . modified ring structure |
| 15/907 | {in mammalian cells} | 2310/3231 | having an additional ring, e.g. LNA, ENA |
| 2310/312 | | 2310/3233 | Morpholino-type ring |
| | | 2310/3235 | having the O of the ribose replaced by another atom |
| | | 2310/33 | . . of the base |
| | | 2310/331 | . . . Universal or degenerate base |
| | | 2310/332 | . . . Abasic residue |
| | | 2310/333 | . . . Modified A |
| | | 2310/334 | . . . Modified C |
| | | 2310/3341 | 5-Methylcytosine |
| | | 2310/335 | . . . Modified T or U |
| | | 2310/336 | . . . Modified G |
| | | 2310/337 | . . . in alpha-anomeric form |
| | | 2310/34 | . . Spatial arrangement of the modifications |
| | | 2310/341 | . . . Gapmers, i.e. of the type ===== |
| | | 2310/342 | . . . Hemimers, i.e. of the type ===== |
| | | 2310/343 | . . . having patterns, e.g. ==-==-==-== |
| | | 2310/344 | . . . Position-specific modifications, e.g. on every purine, at the 3'-end |
| | | 2310/345 | . . . having at least two different backbone modifications |
| | | 2310/346 | . . . having a combination of backbone and sugar modifications |
| | | 2310/35 | . . Nature of the modification |
| | | 2310/351 | . . . Conjugate |
| | | 2310/3511 | intercalating or cleaving agent |
| | | 2310/3513 | Protein; Peptide |
| | | 2310/3515 | Lipophilic moiety, e.g. cholesterol |
| | | 2310/3517 | Marker; Tag |
| | | 2310/3519 | Fusion with another nucleic acid |
| | | 2310/352 | . . . linked to the nucleic acid via a carbon atom |
| | | 2310/3521 | Methyl |
| | | 2310/3523 | Allyl |
| | | 2310/3525 | MOE, methoxyethoxy |
| | | 2310/3527 | Other alkyl chain |
| | | 2310/3529 | Aromatic substituent |
| | | 2310/353 | . . . linked to the nucleic acid via an atom other than carbon |
| | | 2310/3531 | Hydrogen |
| | | 2310/3533 | Halogen |
| | | 2310/3535 | Nitrogen |
| | | 2310/50 | . Physical structure |
| | | 2310/51 | . . in polymeric form, e.g. multimers, concatemers |
| | | 2310/52 | . . branched |
| | | 2310/53 | . . partially self-complementary or closed |
| 2303/00 | Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids | | |
| | NOTE | | |
| | Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111 | | |
| 2310/00 | Structure or type of the nucleic acid | | |
| 2310/10 | . Type of nucleic acid | | |
| 2310/11 | . . Antisense | | |
| 2310/111 | . . . spanning the whole gene, or a large part of it | | |
| 2310/113 | . . . targeting other non-coding nucleic acids, e.g. antagomirs | | |
| 2310/12 | . . catalytic nucleic acids, e.g. ribozymes | | |
| 2310/121 | . . . Hammerhead | | |
| 2310/122 | . . . Hairpin | | |
| 2310/123 | . . . Hepatitis delta | | |
| 2310/124 | . . . based on group I or II introns | | |
| 2310/1241 | Tetrahymena | | |
| 2310/126 | . . . involving RNase P | | |
| 2310/127 | . . . DNAAzymes | | |
| 2310/128 | . . . processing or releasing ribozyme | | |
| 2310/13 | . . Decoys | | |
| 2310/14 | . . interfering N.A. | | |
| 2310/141 | . . . MicroRNAs, miRNAs | | |
| 2310/15 | . . Nucleic acids forming more than 2 strands, e.g. TFOs | | |
| 2310/151 | . . . more than 3 strands, e.g. tetrads, H-DNA | | |
| 2310/152 | . . . on a single-stranded target, e.g. fold-back TFOs | | |
| 2310/153 | . . . with the aid of a protein, e.g. recombinase | | |
| 2310/16 | . . Aptamers | | |
| 2310/17 | . . Immunomodulatory nucleic acids | | |
| 2310/18 | . . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17) | | |
| 2310/20 | . . involving clustered regularly interspaced short palindromic repeats [CRISPRs] | | |
| 2310/30 | . Chemical structure | | |
| 2310/31 | . . of the backbone | | |
| 2310/311 | . . . Phosphotriesters | | |
| 2310/312 | . . . Phosphonates | | |

- 2310/531 . . . Stem-loop; Hairpin
- 2310/532 . . . Closed or circular
- 2310/533 . . . having a mismatch or nick in at least one of the strands

2320/00 Applications; Uses

- 2320/10 . . in screening processes
- 2320/11 . . for the determination of target sites, i.e. of active nucleic acids
- 2320/12 . . in functional genomics, i.e. for the determination of gene function
- 2320/13 . . in a process of directed evolution, e.g. SELEX, acquiring a new function
- 2320/30 . Special therapeutic applications
- 2320/31 . . Combination therapy
- 2320/32 . . Special delivery means, e.g. tissue-specific
- 2320/33 . . Alteration of splicing
- 2320/34 . . Allele or polymorphism specific uses
- 2320/35 . . based on a specific dosage / administration regimen
- 2320/50 . Methods for regulating/modulating their activity
- 2320/51 . . modulating the chemical stability, e.g. nuclease-resistance
- 2320/52 . . modulating the physical stability, e.g. GC-content
- 2320/53 . . reducing unwanted side-effects

2330/00 Production

- 2330/10 . naturally occurring
- 2330/30 . chemically synthesised
- 2330/31 . . Libraries, arrays
- 2330/50 . Biochemical production, i.e. in a transformed host cell
- 2330/51 . . Specially adapted vectors

2500/00 Specific components of cell culture medium

- 2500/02 . Atmosphere, e.g. low oxygen conditions
- 2500/05 . Inorganic components
- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- 2500/14 Calcium; Ca chelators; Calcitonin
- 2500/16 Magnesium; Mg chelators
- 2500/20 . . . Transition metals
- 2500/22 Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- 2500/24 Iron; Fe chelators; Transferrin
- 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
- 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- 2500/32 . . Amino acids
- 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- 2500/34 . . Sugars
- 2500/35 . . Polyols, e.g. glycerin, inositol
- 2500/36 . . Lipids
- 2500/38 . . Vitamins
- 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- 2500/44 . . Thiols, e.g. mercaptoethanol

- 2500/46 . . Amines, e.g. putrescine
- 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- 2500/62 . . DMSO
- 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- 2500/72 . . from bacteria
- 2500/74 . . from fungi, e.g. yeasts
- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012.

The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

2501/00 Active agents used in cell culture processes, e.g. differentiation

NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
- 2501/05 . Adjuvants
- 2501/051 . . Lipid A (MPA, MPL)
- 2501/052 . . Lipopolysaccharides [LPS]
- 2501/054 . . Muramyl peptides
- 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
- 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- 2501/065 . Modulators of histone acetylation
- 2501/07 . Heat shock proteins
- 2501/10 . Growth factors
- 2501/105 . . Insulin-like growth factors [IGF]
- 2501/11 . . Epidermal growth factor [EGF]
- 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
- 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)

| | | | |
|-----------|--|-----------|--|
| 2501/117 | . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12) | 2501/2331 | . . . Interleukin-31 (IL-31) |
| 2501/119 | . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 | 2501/2332 | . . . Interleukin-32 (IL-32) |
| 2501/12 | . . Hepatocyte growth factor [HGF] | 2501/2333 | . . . Interleukin-33 (IL-33) |
| 2501/125 | . . Stem cell factor [SCF], c-kit ligand [KL] | 2501/2334 | . . . Interleukin-34 (IL-34) |
| 2501/13 | . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins | 2501/2335 | . . . Interleukin-35 (IL-35) |
| 2501/135 | . . Platelet-derived growth factor [PDGF] | 2501/235 | . . . Leukemia inhibitory factor [LIF] |
| 2501/14 | . . Erythropoietin [EPO] | 2501/237 | . . Oncostatin M [OSM] |
| 2501/145 | . . Thrombopoietin [TPO] | 2501/24 | . . Interferons [IFN] |
| 2501/148 | . . Transforming growth factor alpha [TGF- α] | 2501/25 | . . Tumour necrosing factors [TNF] |
| 2501/15 | . . Transforming growth factor beta (TGF- β) | 2501/26 | . . Flt-3 ligand (CD135L, flk-2 ligand) |
| 2501/155 | . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor | 2501/30 | . Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85) |
| 2501/16 | . . Activin; Inhibin; Mullerian inhibiting substance | 2501/305 | . . Growth hormone [GH], aka. somatotropin |
| 2501/165 | . . Vascular endothelial growth factor [VEGF] | 2501/31 | . . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins |
| 2501/17 | . . Angiopoietin | 2501/315 | . . Prolactin |
| 2501/175 | . . Cardiotrophin | 2501/32 | . . Angiotensins [AT], angiotensinogen |
| 2501/18 | . . Liver cell growth factor (LCGF, Gly-His-Lys) | 2501/33 | . . Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105) |
| 2501/185 | . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL) | 2501/335 | . . Glucagon; Glucagon-like peptide [GLP]; Exendin |
| 2501/19 | . . Growth and differentiation factors [GDF] | 2501/34 | . . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin |
| 2501/195 | . . Heregulin, neu differentiation factor | 2501/345 | . . Gastrin; Cholecystokinins [CCK] |
| 2501/20 | . Cytokines; Chemokines | 2501/35 | . . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP] |
| 2501/21 | . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4 | 2501/355 | . . Leptin |
| 2501/22 | . . Colony stimulating factors (G-CSF, GM-CSF) | 2501/36 | . . Somatostatin |
| 2501/23 | . . Interleukins [IL] | 2501/365 | . . Endothelin |
| 2501/2301 | . . . Interleukin-1 (IL-1) | 2501/37 | . . Parathyroid hormone [PTH] |
| 2501/2302 | . . . Interleukin-2 (IL-2) | 2501/375 | . . Thyroid stimulating hormone [TSH] |
| 2501/2303 | . . . Interleukin-3 (IL-3) | 2501/38 | . . with nuclear receptors |
| 2501/2304 | . . . Interleukin-4 (IL-4) | 2501/385 | . . . of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] |
| 2501/2305 | . . . Interleukin-5 (IL-5) | 2501/39 | . . . Steroid hormones |
| 2501/2306 | . . . Interleukin-6 (IL-6) | 2501/392 | Sexual steroids |
| 2501/2307 | . . . Interleukin-7 (IL-7) | 2501/395 | . . . Thyroid hormones |
| 2501/2308 | . . . Interleukin-8 (IL-8) | 2501/40 | . Regulators of development |
| 2501/2309 | . . . Interleukin-9 (IL-9) | 2501/405 | . . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases |
| 2501/231 | . . . Interleukin-10 (IL-10) | 2501/41 | . . Hedgehog proteins; Cyclopamine (inhibitor) |
| 2501/2311 | . . . Interleukin-11 (IL-11) | 2501/415 | . . Wnt; Frizzled |
| 2501/2312 | . . . Interleukin-12 (IL-12) | 2501/42 | . . Notch; Delta; Jagged; Serrate |
| 2501/2313 | . . . Interleukin-13 (IL-13) | 2501/48 | . . Regulators of apoptosis |
| 2501/2314 | . . . Interleukin-14 (IL-14) | 2501/50 | . Cell markers; Cell surface determinants |
| 2501/2315 | . . . Interleukin-15 (IL-15) | 2501/505 | . . CD4; CD8 |
| 2501/2316 | . . . Interleukin-16 (IL-16) | 2501/51 | . . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) |
| 2501/2317 | . . . Interleukin-17 (IL-17) | 2501/515 | . . CD3, T-cell receptor complex |
| 2501/2318 | . . . Interleukin-18 (IL-18) | 2501/52 | . . CD40, CD40-ligand (CD154) |
| 2501/2319 | . . . Interleukin-19 (IL-19) | 2501/53 | . . CD2 |
| 2501/232 | . . . Interleukin-20 (IL-20) | 2501/58 | . . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) |
| 2501/2321 | . . . Interleukin-21 (IL-21) | 2501/585 | . . Integrins |
| 2501/2322 | . . . Interleukin-22 (IL-22) | 2501/59 | . . Lectins |
| 2501/2323 | . . . Interleukin-23 (IL-23) | 2501/599 | . . with CD designations not provided for elsewhere |
| 2501/2324 | . . . Interleukin-24 (IL-24) | 2501/60 | . Transcription factors |
| 2501/2325 | . . . Interleukin-25 (IL-25) | 2501/602 | . . Sox-2 |
| 2501/2326 | . . . Interleukin-26 (IL-26) | 2501/603 | . . Oct-3/4 |
| 2501/2327 | . . . Interleukin-27 (IL-27) | 2501/604 | . . Klf-4 |
| 2501/2328 | . . . Interleukin-28 (IL-28) | | |
| 2501/2329 | . . . Interleukin-29 (IL-29) | | |
| 2501/233 | . . . Interleukin-30 (IL-30) | | |

| | |
|----------|--|
| 2501/605 | . . Nanog |
| 2501/606 | . . c-Myc |
| 2501/608 | . . Lin28 |
| 2501/65 | . MicroRNA |
| 2501/70 | . Enzymes |
| 2501/71 | . . Oxidoreductases (EC 1.) |
| 2501/72 | . . Transferases (EC 2.) (acetylation of histones C12N 2501/065) |
| 2501/724 | . . . Glycosyltransferases (EC 2.4.) |
| 2501/727 | . . . Kinases (EC 2.7.) |
| 2501/73 | . . Hydrolases (EC 3.) |
| 2501/734 | . . . Proteases (EC 3.4.) |
| 2501/80 | . Neurotransmitters; Neurohormones |
| 2501/805 | . . Acetylcholine |
| 2501/81 | . . Adrenaline |
| 2501/815 | . . Dopamine |
| 2501/82 | . . Histamine |
| 2501/825 | . . Serotonin (5-HT); Melatonin |
| 2501/83 | . . Tachykinins, e.g. substance P |
| 2501/835 | . . Neuropeptide Y [NPY]; Peptide YY [PYY] |
| 2501/84 | . . Excitatory amino acids |
| 2501/845 | . . Gamma amino butyric acid [GABA] |
| 2501/85 | . Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin |
| 2501/855 | . . Corticotropin [ACTH] |
| 2501/86 | . . Melanocyte-stimulating hormone [MSH] |
| 2501/90 | . Polysaccharides |
| 2501/905 | . . Hyaluronic acid |
| 2501/91 | . . Heparin |
| 2501/998 | . Proteins not provided for elsewhere |

NOTE

Classification by pathway does not apply.

| | |
|----------|--|
| 2501/999 | . Small molecules not provided for elsewhere |
|----------|--|

NOTE

Classification by pathway does not apply.

| | |
|----------------|---|
| 2502/00 | Coculture with; Conditioned medium produced by |
| 2502/02 | . embryonic cells |
| 2502/025 | . . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly |
| 2502/03 | . non-embryonic pluripotent stem cells |
| 2502/04 | . germ cells |
| 2502/07 | . endocrine cells |
| 2502/072 | . . adrenal cells |
| 2502/074 | . . pinealocytes |
| 2502/076 | . . pituitary cells |
| 2502/078 | . . thyroid, parathyroid cells |
| 2502/08 | . cells of the nervous system |
| 2502/081 | . . neurons |
| 2502/083 | . . sensory transducers |
| 2502/085 | . . eye cells |
| 2502/086 | . . glial cells |
| 2502/088 | . . neural stem cells |
| 2502/09 | . epidermal cells, skin cells, oral mucosa cells |
| 2502/091 | . . melanocytes |
| 2502/092 | . . hair cells |
| 2502/094 | . . keratinocytes |
| 2502/095 | . . mammary cells |
| 2502/097 | . . oral mucosa cells |

| | |
|-----------|---|
| 2502/098 | . . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands |
| 2502/11 | . blood or immune system cells |
| 2502/1107 | . . B cells |
| 2502/1114 | . . T cells |
| 2502/1121 | . . Dendritic cells |
| 2502/1128 | . . Erythrocytes |
| 2502/1135 | . . Granulocytes |
| 2502/1142 | . . Osteoclasts |
| 2502/115 | . . Platelets, megakaryocytes |
| 2502/1157 | . . Monocytes, macrophages |
| 2502/1164 | . . NK cells |
| 2502/1171 | . . Haematopoietic stem cells |
| 2502/1178 | . . Spleen cells |
| 2502/1185 | . . Thymus cells |
| 2502/1192 | . . Lymphatic cells |
| 2502/13 | . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" |
| 2502/1305 | . . Adipocytes |
| 2502/1311 | . . Osteocytes, osteoblasts, odontoblasts |
| 2502/1317 | . . Chondrocytes |
| 2502/1323 | . . Adult fibroblasts |
| 2502/1329 | . . Cardiomyocytes |
| 2502/1335 | . . Skeletal muscle cells, myocytes, myoblasts, myotubes |
| 2502/1341 | . . Tenocytes, cells from tendons and ligaments |
| 2502/1347 | . . Smooth muscle cells |
| 2502/1352 | . . Mesenchymal stem cells |
| 2502/1358 | . . . Bone marrow mesenchymal stem cells (BM-MS) |
| 2502/1364 | . . . Dental pulp stem cells, dental follicle stem cells |
| 2502/137 | . . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood |
| 2502/1376 | . . . Mesenchymal stem cells from hair follicles |
| 2502/1382 | . . . Adipose-derived stem cells [ADSC], adipose stromal stem cells |
| 2502/1388 | . . . Mesenchymal stem cells from other natural sources |
| 2502/1394 | . . Bone marrow stromal cells; whole marrow |
| 2502/14 | . hepatocytes |
| 2502/22 | . pancreatic cells |
| 2502/23 | . Gastro-intestinal tract cells |
| 2502/24 | . Genital tract cells, non-germinal cells from gonads |
| 2502/243 | . . Cells of the female genital tract, non-germinal ovarian cells |
| 2502/246 | . . Cells of the male genital tract, non-germinal testis cells |
| 2502/25 | . Urinary tract cells, renal cells |
| 2502/253 | . . Bladder cells |
| 2502/256 | . . Renal cells |
| 2502/27 | . Lung cells, respiratory tract cells |
| 2502/28 | . Vascular endothelial cells |
| 2502/30 | . tumour cells |
| 2502/45 | . Artificially induced pluripotent stem cells |
| 2502/50 | . invertebrate cells |
| 2502/70 | . Non-animal cells |
| 2502/99 | . genetically modified cells |

NOTE

Use [C12N 2501/00](#) to index the expressed products.

| | |
|----------------|------------------------------------|
| 2503/00 | Use of cells in diagnostics |
|----------------|------------------------------------|

- 2503/02 . Drug screening
- 2503/04 . Screening or testing on artificial tissues
- 2503/06 . . Screening or testing on artificial skin
- 2506/00** **Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells**

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

- 2506/02 . from embryonic cells
- 2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta
- 2506/03 . from non-embryonic pluripotent stem cells
- 2506/04 . from germ cells
- 2506/07 . from endocrine cells
- 2506/072 . . from adrenal cells
- 2506/074 . . from pinealocytes
- 2506/076 . . from pituitary cells
- 2506/078 . . from thyroid, parathyroid cells
- 2506/08 . from cells of the nervous system
- 2506/09 . from epidermal cells, from skin cells, from oral mucosa cells
- 2506/091 . . from melanocytes
- 2506/092 . . from hair cells
- 2506/094 . . from keratinocytes
- 2506/095 . . from mammary cells
- 2506/097 . . from oral mucosa cells
- 2506/098 . . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- 2506/11 . from blood or immune system cells
- 2506/115 . . from monocytes, from macrophages
- 2506/13 . from connective tissue cells, from mesenchymal cells
- 2506/1307 . . from adult fibroblasts
- 2506/1315 . . from cardiomyocytes
- 2506/1323 . . from skeletal muscle cells
- 2506/133 . . from tenocytes
- 2506/1338 . . from smooth muscle cells
- 2506/1346 . . from mesenchymal stem cells
- 2506/1353 . . . from bone marrow mesenchymal stem cells (BM-MSC)
- 2506/1361 . . . from dental pulp or dental follicle stem cells
- 2506/1369 . . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
- 2506/1376 . . . from mesenchymal stem cells derived from hair follicles
- 2506/1384 . . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- 2506/1392 . . . from mesenchymal stem cells from other natural sources
- 2506/14 . from hepatocytes
- 2506/22 . from pancreatic cells
- 2506/23 . from cells of the gastro-intestinal tract
- 2506/24 . from cells of the genital tract, from non-germinal gonad cells
- 2506/243 . . from cells of the female genital tract cells, from non-germinal ovarian cells

- 2506/246 . . from cells of the male genital tract cells, from non-germinal testis cells
- 2506/25 . from renal cells, from cells of the urinary tract
- 2506/27 . from lung cells, from cells of the respiratory tract
- 2506/28 . from vascular endothelial cells
- 2506/30 . from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- 2506/45 . from artificially induced pluripotent stem cells
- 2509/00** **Methods for the dissociation of cells, e.g. specific use of enzymes**
- 2509/10 . Mechanical dissociation
- 2510/00** **Genetically modified cells**
- 2510/02 . Cells for production
- 2510/04 . Immortalised cells
- 2511/00** **Cells for large scale production**
- 2513/00** **3D culture**
- 2517/00** **Cells related to new breeds of animals**
- 2517/02 . Cells from transgenic animals
- 2517/04 . Cells produced using nuclear transfer
- 2517/10 . Conditioning of cells for *in vitro* fecondation or nuclear transfer
- 2521/00** **Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . Sound, e.g. ultrasounds
- 2523/00** **Culture process characterised by temperature**
- 2525/00** **Culture process characterised by gravity, e.g. microgravity**
- 2527/00** **Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00** **Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . Stimulation by light
- 2531/00** **Microcarriers**
- 2533/00** **Supports or coatings for cell culture, characterised by material**
- 2533/10 . Mineral substrates
- 2533/12 . . Glass
- 2533/14 . . Ceramic
- 2533/18 . . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- 2533/20 . Small organic molecules
- 2533/30 . Synthetic polymers ([thermoreactive polymers, e.g. PNIPAm, C12N 2539/10](#))
- 2533/32 . . Polylysine, polyornithine
- 2533/40 . . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- 2533/50 . Proteins
- 2533/52 . . Fibronectin; Laminin
- 2533/54 . . Collagen; Gelatin
- 2533/56 . . Fibrin; Thrombin
- 2533/70 . Polysaccharides

- 2533/72 . . Chitin, chitosan
- 2533/74 . . Alginate
- 2533/76 . . Agarose, agar-agar
- 2533/78 . . Cellulose
- 2533/80 . . Hyaluronan
- 2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- 2533/92 . . Amnion; Decellularised dermis or mucosa
- 2535/00 Supports or coatings for cell culture characterised by topography**
- 2535/10 . Patterned coating
- 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment**
- 2537/10 . Cross-linking
- 2539/00 Supports and/or coatings for cell culture characterised by properties**
- 2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating
- 2700/00 Viruses**
- 2710/00 dsDNA Viruses (not used)**
- 2710/00011 . dsDNA Viruses
- 2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/00023 . . Virus like particles [VLP]
- 2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated in vivo effect
- 2710/00088 . . For redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]
- 2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 viral genome or elements thereof as genetic vector
- 2710/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 Special targeting system for viral vectors
- 2710/10051 . . . Methods of production or purification of viral material
- 2710/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10061 . . . Methods of inactivation or attenuation
- 2710/10062 by genetic engineering
- 2710/10063 by chemical treatment
- 2710/10064 by serial passage
- 2710/10071 . . . Demonstrated in vivo effect
- 2710/10088 . . . For redistribution
- 2710/10111 . . . Atadenovirus, e.g. ovine adenovirus D
- 2710/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10123 Virus like particles [VLP]
- 2710/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10141 Use of virus, viral particle or viral elements as a vector
- 2710/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10143 viral genome or elements thereof as genetic vector
- 2710/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10145 Special targeting system for viral vectors
- 2710/10151 Methods of production or purification of viral material

| | | | |
|------------|---|------------|---|
| 2710/10152 | relating to complementing cells and packaging systems for producing virus or viral particles | 2710/10334 | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/10161 | Methods of inactivation or attenuation | 2710/10341 | Use of virus, viral particle or viral elements as a vector |
| 2710/10162 | by genetic engineering | 2710/10342 | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/10163 | by chemical treatment | 2710/10343 | viral genome or elements thereof as genetic vector |
| 2710/10164 | by serial passage | 2710/10344 | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2710/10171 | Demonstrated <u>in vivo</u> effect | 2710/10345 | Special targeting system for viral vectors |
| 2710/10188 | For redistribution | 2710/10351 | Methods of production or purification of viral material |
| 2710/10211 | Aviadenvirus, e.g. fowl adenovirus A | 2710/10352 | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2710/10221 | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2710/10361 | Methods of inactivation or attenuation |
| 2710/10222 | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2710/10362 | by genetic engineering |
| 2710/10223 | Virus like particles [VLP] | 2710/10363 | by chemical treatment |
| 2710/10231 | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2710/10364 | by serial passage |
| 2710/10232 | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2710/10371 | Demonstrated <u>in vivo</u> effect |
| 2710/10233 | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2710/10388 | For redistribution |
| 2710/10234 | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2710/12011 | Asfarviridae |
| 2710/10241 | Use of virus, viral particle or viral elements as a vector | 2710/12021 | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2710/10242 | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2710/12022 | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2710/10243 | viral genome or elements thereof as genetic vector | 2710/12023 | Virus like particles [VLP] |
| 2710/10244 | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2710/12031 | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2710/10245 | Special targeting system for viral vectors | 2710/12032 | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2710/10251 | Methods of production or purification of viral material | 2710/12033 | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2710/10252 | relating to complementing cells and packaging systems for producing virus or viral particles | 2710/12034 | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/10261 | Methods of inactivation or attenuation | 2710/12041 | Use of virus, viral particle or viral elements as a vector |
| 2710/10262 | by genetic engineering | 2710/12042 | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/10263 | by chemical treatment | 2710/12043 | viral genome or elements thereof as genetic vector |
| 2710/10264 | by serial passage | 2710/12044 | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2710/10271 | Demonstrated <u>in vivo</u> effect | 2710/12045 | Special targeting system for viral vectors |
| 2710/10288 | For redistribution | 2710/12051 | Methods of production or purification of viral material |
| 2710/10311 | Mastadenovirus, e.g. human or simian adenoviruses | 2710/12052 | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2710/10321 | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2710/12061 | Methods of inactivation or attenuation |
| 2710/10322 | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2710/12062 | by genetic engineering |
| 2710/10323 | Virus like particles [VLP] | 2710/12063 | by chemical treatment |
| 2710/10331 | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2710/12064 | by serial passage |
| 2710/10332 | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2710/12071 | Demonstrated <u>in vivo</u> effect |
| 2710/10333 | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2710/12088 | For redistribution |
| | | 2710/14011 | Baculoviridae |

- 2710/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14023 . . . Virus like particles [VLP]
- 2710/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14043 . . . viral genome or elements thereof as genetic vectore
- 2710/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14045 . . . Special targeting system for viral vectors
- 2710/14051 . . . Methods of production or purification of viral material
- 2710/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14061 . . . Methods of inactivation or attenuation
- 2710/14062 . . . by genetic engineering
- 2710/14063 . . . by chemical treatment
- 2710/14064 . . . by serial passage
- 2710/14071 . . . Demonstrated in vivo effect
- 2710/14088 . . . For redistribution
- 2710/14111 . . . Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- 2710/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14123 . . . Virus like particles [VLP]
- 2710/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14141 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14143 . . . viral genome or elements thereof as genetic vector
- 2710/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14145 . . . Special targeting system for viral vectors
- 2710/14151 . . . Methods of production or purification of viral material
- 2710/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14161 . . . Methods of inactivation or attenuation
- 2710/14162 . . . by genetic engineering
- 2710/14163 . . . by chemical treatment
- 2710/14164 . . . by serial passage
- 2710/14171 . . . Demonstrated in vivo effect
- 2710/14188 . . . For redistribution
- 2710/16011 . . . Herpesviridae
- 2710/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16023 . . . Virus like particles [VLP]
- 2710/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/16042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16043 . . . viral genome or elements thereof as genetic vector
- 2710/16044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16045 . . . Special targeting system for viral vectors
- 2710/16051 . . . Methods of production or purification of viral material
- 2710/16052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16061 . . . Methods of inactivation or attenuation
- 2710/16062 . . . by genetic engineering
- 2710/16063 . . . by chemical treatment
- 2710/16064 . . . by serial passage
- 2710/16071 . . . Demonstrated in vivo effect
- 2710/16088 . . . For redistribution
- 2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5
- 2710/16121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 . . . Virus like particles [VLP]
- 2710/16131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2710/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 Use of virus, viral particle or viral elements as a vector
- 2710/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 viral genome or elements thereof as genetic vector
- 2710/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 Special targeting system for viral vectors
- 2710/16151 Methods of production or purification of viral material
- 2710/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 Methods of inactivation or attenuation
- 2710/16162 by genetic engineering
- 2710/16163 by chemical treatment
- 2710/16164 by serial passage
- 2710/16171 Demonstrated in vivo effect
- 2710/16188 For redistribution
- 2710/16211 Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 Virus like particles [VLP]
- 2710/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16241 Use of virus, viral particle or viral elements as a vector
- 2710/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16243 viral genome or elements thereof as genetic vector
- 2710/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16245 Special targeting system for viral vectors
- 2710/16251 Methods of production or purification of viral material
- 2710/16252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16261 Methods of inactivation or attenuation
- 2710/16262 by genetic engineering
- 2710/16263 by chemical treatment
- 2710/16264 by serial passage
- 2710/16271 Demonstrated in vivo effect
- 2710/16288 For redistribution
- 2710/16311 Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- 2710/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 Virus like particles [VLP]
- 2710/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 Use of virus, viral particle or viral elements as a vector
- 2710/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 viral genome or elements thereof as genetic vector
- 2710/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 Special targeting system for viral vectors
- 2710/16351 Methods of production or purification of viral material
- 2710/16352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16361 Methods of inactivation or attenuation
- 2710/16362 by genetic engineering
- 2710/16363 by chemical treatment
- 2710/16364 by serial passage
- 2710/16371 Demonstrated in vivo effect
- 2710/16388 For redistribution
- 2710/16411 Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16423 Virus like particles [VLP]
- 2710/16431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16441 Use of virus, viral particle or viral elements as a vector
- 2710/16442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16443 viral genome or elements thereof as genetic vector

| | | | | | |
|------------|-----------|---|------------|-----------|---|
| 2710/16444 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2710/16633 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2710/16445 | | Special targeting system for viral vectors | 2710/16634 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/16451 | | Methods of production or purification of viral material | 2710/16641 | | Use of virus, viral particle or viral elements as a vector |
| 2710/16452 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2710/16642 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/16461 | | Methods of inactivation or attenuation | 2710/16643 | | viral genome or elements thereof as genetic vector |
| 2710/16462 | | by genetic engineering | 2710/16644 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2710/16463 | | by chemical treatment | 2710/16645 | | Special targeting system for viral vectors |
| 2710/16464 | | by serial passage | 2710/16651 | | Methods of production or purification of viral material |
| 2710/16471 | | Demonstrated <u>in vivo</u> effect | 2710/16652 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2710/16488 | | For redistribution | 2710/16661 | | Methods of inactivation or attenuation |
| 2710/16511 | | Roseolovirus, e.g. human herpesvirus 6, 7 | 2710/16662 | | by genetic engineering |
| 2710/16521 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2710/16663 | | by chemical treatment |
| 2710/16522 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2710/16664 | | by serial passage |
| 2710/16523 | | Virus like particles [VLP] | 2710/16671 | | Demonstrated <u>in vivo</u> effect |
| 2710/16531 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2710/16688 | | For redistribution |
| 2710/16532 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2710/16711 | | Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies |
| 2710/16533 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2710/16721 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2710/16534 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral | 2710/16722 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2710/16541 | | Use of virus, viral particle or viral elements as a vector | 2710/16723 | | Virus like particles [VLP] |
| 2710/16542 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2710/16731 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2710/16543 | | viral genome or elements thereof as genetic vector | 2710/16732 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2710/16544 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2710/16733 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2710/16545 | | Special targeting system for viral vectors | 2710/16734 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/16551 | | Methods of production or purification of viral material | 2710/16741 | | Use of virus, viral particle or viral elements as a vector |
| 2710/16552 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2710/16742 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/16561 | | Methods of inactivation or attenuation | 2710/16743 | | viral genome or elements thereof as genetic vector |
| 2710/16562 | | by genetic engineering | 2710/16744 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2710/16563 | | by chemical treatment | 2710/16745 | | Special targeting system for viral vectors |
| 2710/16564 | | by serial passage | 2710/16751 | | Methods of production or purification of viral material |
| 2710/16571 | | Demonstrated <u>in vivo</u> effect | 2710/16752 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2710/16588 | | For redistribution | 2710/16761 | | Methods of inactivation or attenuation |
| 2710/16611 | | Simplexvirus, e.g. human herpesvirus 1, 2 | 2710/16762 | | by genetic engineering |
| 2710/16621 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2710/16763 | | by chemical treatment |
| 2710/16622 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2710/16764 | | by serial passage |
| 2710/16623 | | Virus like particles [VLP] | | | |
| 2710/16631 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | | | |
| 2710/16632 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | | | |

- 2710/16771 Demonstrated in vivo effect
- 2710/16788 For redistribution
- 2710/18011 Nimaviridae
- 2710/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 Virus like particles [VLP]
- 2710/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 Use of virus, viral particle or viral elements as a vector
- 2710/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 viral genome or elements thereof as genetic vector
- 2710/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 Special targeting system for viral vectors
- 2710/18051 Methods of production or purification of viral material
- 2710/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/18061 Methods of inactivation or attenuation
- 2710/18062 by genetic engineering
- 2710/18063 by chemical treatment
- 2710/18064 by serial passage
- 2710/18071 Demonstrated in vivo effect
- 2710/18088 For redistribution
- 2710/20011 Papillomaviridae
- 2710/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 Virus like particles [VLP]
- 2710/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 Use of virus, viral particle or viral elements as a vector
- 2710/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 viral genome or elements thereof as genetic vector
- 2710/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 Special targeting system for viral vectors
- 2710/20051 Methods of production or purification of viral material
- 2710/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/20061 Methods of inactivation or attenuation
- 2710/20062 by genetic engineering
- 2710/20063 by chemical treatment
- 2710/20064 by serial passage
- 2710/20071 Demonstrated in vivo effect
- 2710/20088 For redistribution
- 2710/22011 Polyomaviridae, e.g. polyoma, SV40, JC
- 2710/22021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/22023 Virus like particles [VLP]
- 2710/22031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/22032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/22033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/22034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/22041 Use of virus, viral particle or viral elements as a vector
- 2710/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/22043 viral genome or elements thereof as genetic vector
- 2710/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/22045 Special targeting system for viral vectors
- 2710/22051 Methods of production or purification of viral material
- 2710/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/22061 Methods of inactivation or attenuation
- 2710/22062 by genetic engineering
- 2710/22063 by chemical treatment
- 2710/22064 by serial passage
- 2710/22071 Demonstrated in vivo effect
- 2710/22088 For redistribution
- 2710/24011 Poxviridae
- 2710/24021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24023 Virus like particles [VLP]
- 2710/24031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

| | | | | | |
|------------|-----------|---|----------------|-----------|---|
| 2710/24033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2710/24188 | | For redistribution |
| 2710/24034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2710/24211 | . . . | Parapoxvirus, e.g. Orf virus |
| 2710/24041 | . . . | Use of virus, viral particle or viral elements as a vector | 2710/24221 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2710/24042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2710/24222 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2710/24043 | | viral genome or elements thereof as genetic vector | 2710/24223 | | Virus like particles [VLP] |
| 2710/24044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2710/24231 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2710/24045 | | Special targeting system for viral vectors | 2710/24232 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2710/24051 | . . . | Methods of production or purification of viral material | 2710/24233 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2710/24052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2710/24234 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/24061 | . . . | Methods of inactivation or attenuation | 2710/24241 | | Use of virus, viral particle or viral elements as a vector |
| 2710/24062 | | by genetic engineering | 2710/24242 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/24063 | | by chemical treatment | 2710/24243 | | viral genome or elements thereof as genetic vector |
| 2710/24064 | | by serial passage | 2710/24244 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2710/24071 | . . . | Demonstrated <u>in vivo</u> effect | 2710/24245 | | Special targeting system for viral vectors |
| 2710/24088 | . . . | For redistribution | 2710/24251 | | Methods of production or purification of viral material |
| 2710/24111 | . . . | Orthopoxvirus, e.g. vaccinia virus, variola | 2710/24252 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2710/24121 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2710/24261 | | Methods of inactivation or attenuation |
| 2710/24122 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2710/24262 | | by genetic engineering |
| 2710/24123 | | Virus like particles [VLP] | 2710/24263 | | by chemical treatment |
| 2710/24131 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2710/24264 | | by serial passage |
| 2710/24132 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2710/24271 | | Demonstrated <u>in vivo</u> effect |
| 2710/24133 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2710/24288 | | For redistribution |
| 2710/24134 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2720/00 | | dsRNA Viruses (not used) |
| 2710/24141 | | Use of virus, viral particle or viral elements as a vector | 2720/00011 | . . | dsRNA Viruses |
| 2710/24142 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2720/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2710/24143 | | viral genome or elements thereof as genetic vector | 2720/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2710/24144 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2720/00023 | . . | Virus like particles [VLP] |
| 2710/24145 | | Special targeting system for viral vectors | 2720/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2710/24151 | | Methods of production or purification of viral material | 2720/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2710/24152 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2720/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2710/24161 | | Methods of inactivation or attenuation | 2720/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2710/24162 | | by genetic engineering | 2720/00041 | . . | Use of virus, viral particle or viral elements as a vector |
| 2710/24163 | | by chemical treatment | 2720/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2710/24164 | | by serial passage | 2720/00043 | . . . | viral genome or elements thereof as genetic vector |
| 2710/24171 | | Demonstrated <u>in vivo</u> effect | | | |

- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . . Demonstrated in vivo effect
- 2720/00088 . . . For redistribution
- 2720/10011 . . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vectorn
- 2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 viral genome or elements thereof as genetic vector
- 2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 Special targeting system for viral vectors
- 2720/10051 Methods of production or purification of viral material
- 2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 Methods of inactivation or attenuation
- 2720/10062 by genetic engineering
- 2720/10063 by chemical treatment
- 2720/10064 by serial passage
- 2720/10071 Demonstrated in vivo effect
- 2720/10088 For redistribution
- 2720/12011 . . . Reoviridae
- 2720/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 . . . Virus like particles [VLP]
- 2720/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 viral genome or elements thereof as genetic vector
- 2720/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 Special targeting system for viral vectors
- 2720/12051 Methods of production or purification of viral material
- 2720/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 Methods of inactivation or attenuation
- 2720/12062 by genetic engineering
- 2720/12063 by chemical treatment
- 2720/12064 by serial passage
- 2720/12071 Demonstrated in vivo effect
- 2720/12088 For redistribution
- 2720/12111 Orbivirus, e.g. bluetongue virus
- 2720/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 Virus like particles [VLP]
- 2720/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 Use of virus, viral particle or viral elements as a vectorn
- 2720/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12143 viral genome or elements thereof as genetic vector
- 2720/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12145 Special targeting system for viral vectors
- 2720/12151 Methods of production or purification of viral material
- 2720/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12161 Methods of inactivation or attenuation
- 2720/12162 by genetic engineering
- 2720/12163 by chemical treatment
- 2720/12164 by serial passage
- 2720/12171 Demonstrated in vivo effect

- 2720/12188 For redistribution
- 2720/12211 . . . Orthoreovirus, e.g. mammalian orthoreovirus
- 2720/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12223 Virus like particles [VLP]
- 2720/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12241 Use of virus, viral particle or viral elements as a vector
- 2720/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12243 viral genome or elements thereof as genetic vector
- 2720/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12245 Special targeting system for viral vectors
- 2720/12251 Methods of production or purification of viral material
- 2720/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12261 Methods of inactivation or attenuation
- 2720/12262 by genetic engineering
- 2720/12263 by chemical treatment
- 2720/12264 by serial passage
- 2720/12271 Demonstrated in vivo effect
- 2720/12288 For redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 Virus like particles [VLP]
- 2720/12331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 Use of virus, viral particle or viral elements as a vector
- 2720/12342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 viral genome or elements thereof as genetic vector
- 2720/12344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 Special targeting system for viral vectors
- 2720/12351 Methods of production or purification of viral material
- 2720/12352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12361 Methods of inactivation or attenuation
- 2720/12362 by genetic engineering
- 2720/12363 by chemical treatment
- 2720/12364 by serial passage
- 2720/12371 Demonstrated in vivo effect
- 2720/12388 For redistribution
- 2730/00** **Reverse Transcribing DNA Viruses (not used)**
- 2730/00011 . Reverse Transcribing DNA Viruses
- 2730/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/00023 . . Virus like particles [VLP]
- 2730/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 . . viral genome or elements thereof as genetic vector
- 2730/00044 . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 . . Special targeting system for viral vectors
- 2730/00051 . . Methods of production or purification of viral material
- 2730/00052 . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . Methods of inactivation or attenuation
- 2730/00062 . . by genetic engineering
- 2730/00063 . . by chemical treatment
- 2730/00064 . . by serial passage
- 2730/00071 . . Demonstrated in vivo effect
- 2730/00088 . . For redistribution
- 2730/10011 . . Hepadnaviridae
- 2730/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 . . . Virus like particles [VLP]
- 2730/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2730/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2730/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 viral genome or elements thereof as genetic vector
- 2730/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 Special targeting system for viral vectors
- 2730/10051 . . . Methods of production or purification of viral material
- 2730/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 . . . Methods of inactivation or attenuation
- 2730/10062 by genetic engineering
- 2730/10063 by chemical treatment
- 2730/10064 by serial passage
- 2730/10071 . . . Demonstrated in vivo effect
- 2730/10088 . . . For redistribution
- 2730/10111 . . . Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 Virus like particles [VLP]
- 2730/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10141 Use of virus, viral particle or viral elements as a vector
- 2730/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10143 viral genome or elements thereof as genetic vector
- 2730/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10145 Special targeting system for viral vectors
- 2730/10151 Methods of production or purification of viral material
- 2730/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10161 Methods of inactivation or attenuation
- 2730/10162 by genetic engineering
- 2730/10163 by chemical treatment
- 2730/10164 by serial passage
- 2730/10171 Demonstrated in vivo effect
- 2730/10188 For redistribution
- 2740/00** **Reverse Transcribing RNA Viruses (not used)**
- 2740/00011 . Reverse Transcribing RNA Viruses
- 2740/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . Virus like particles [VLP]
- 2740/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . Demonstrated in vivo effect
- 2740/00088 . . For redistribution
- 2740/10011 . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

| | | | | | |
|------------|---------|---|------------|---------|---|
| 2740/10043 | | viral genome or elements thereof as genetic vector | 2740/12031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2740/10044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2740/12032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2740/10045 | | Special targeting system for viral vectors | 2740/12033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2740/10051 | | Methods of production or purification of viral material | 2740/12034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/10052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2740/12041 | | Use of virus, viral particle or viral elements as a vector |
| 2740/10061 | | Methods of inactivation or attenuation | 2740/12042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2740/10062 | | by genetic engineering | 2740/12043 | | viral genome or elements thereof as genetic vector |
| 2740/10063 | | by chemical treatment | 2740/12044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/10064 | | by serial passage | 2740/12045 | | Special targeting system for viral vectors |
| 2740/10071 | | Demonstrated <u>in vivo</u> effect | 2740/12051 | | Methods of production or purification of viral material |
| 2740/10088 | | For redistribution | 2740/12052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2740/11011 | | Alpharetrovirus, e.g. avian leucosis virus | 2740/12061 | | Methods of inactivation or attenuation |
| 2740/11021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2740/12062 | | by genetic engineering |
| 2740/11022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2740/12063 | | by chemical treatment |
| 2740/11023 | | Virus like particles [VLP] | 2740/12064 | | by serial passage |
| 2740/11031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2740/12071 | | Demonstrated <u>in vivo</u> effect |
| 2740/11032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2740/12088 | | For redistribution |
| 2740/11033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2740/13011 | | Gammaretrovirus, e.g. murine leukaemia virus |
| 2740/11034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2740/13021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2740/11041 | | Use of virus, viral particle or viral elements as a vector | 2740/13022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2740/11042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2740/13023 | | Virus like particles [VLP] |
| 2740/11043 | | viral genome or elements thereof as genetic vector | 2740/13031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2740/11044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2740/13032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2740/11045 | | Special targeting system for viral vectors | 2740/13033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2740/11051 | | Methods of production or purification of viral material | 2740/13034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/11052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2740/13041 | | Use of virus, viral particle or viral elements as a vector |
| 2740/11061 | | Methods of inactivation or attenuation | 2740/13042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2740/11062 | | by genetic engineering | 2740/13043 | | viral genome or elements thereof as genetic vector |
| 2740/11063 | | by chemical treatment | 2740/13044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/11064 | | by serial passage | 2740/13045 | | Special targeting system for viral vectors |
| 2740/11071 | | Demonstrated <u>in vivo</u> effect | 2740/13051 | | Methods of production or purification of viral material |
| 2740/11088 | | For redistribution | 2740/13052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2740/12011 | | Betaretrovirus, e.g. mouse mammary tumour virus | 2740/13061 | | Methods of inactivation or attenuation |
| 2740/12021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | | | |
| 2740/12022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | | | |
| 2740/12023 | | Virus like particles [VLP] | | | |

| | | | | | |
|------------|-----------|---|------------|-----------|---|
| 2740/13062 | | by genetic engineering | 2740/15043 | | viral genome or elements thereof as genetic vector |
| 2740/13063 | | by chemical treatment | 2740/15044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/13064 | | by serial passage | 2740/15045 | | Special targeting system for viral vectors |
| 2740/13071 | | Demonstrated <u>in vivo</u> effect | 2740/15051 | | Methods of production or purification of viral material |
| 2740/13088 | | For redistribution | 2740/15052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2740/14011 | | Deltaretrovirus, e.g. bovine leukaemia virus | 2740/15061 | | Methods of inactivation or attenuation |
| 2740/14021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2740/15062 | | by genetic engineering |
| 2740/14022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2740/15063 | | by chemical treatment |
| 2740/14023 | | Virus like particles [VLP] | 2740/15064 | | by serial passage |
| 2740/14031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2740/15071 | | Demonstrated <u>in vivo</u> effect |
| 2740/14032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2740/15088 | | For redistribution |
| 2740/14033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2740/16011 | | Human Immunodeficiency Virus, HIV |
| 2740/14034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2740/16021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2740/14041 | | Use of virus, viral particle or viral elements as a vector | 2740/16022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2740/14042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2740/16023 | | Virus like particles [VLP] |
| 2740/14043 | | viral genome or elements thereof as genetic vector | 2740/16031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2740/14044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2740/16032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2740/14045 | | Special targeting system for viral vectors | 2740/16033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2740/14051 | | Methods of production or purification of viral material | 2740/16034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/14052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2740/16041 | | Use of virus, viral particle or viral elements as a vector |
| 2740/14061 | | Methods of inactivation or attenuation | 2740/16042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2740/14062 | | by genetic engineering | 2740/16043 | | viral genome or elements thereof as genetic vector |
| 2740/14063 | | by chemical treatment | 2740/16044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/14064 | | by serial passage | 2740/16045 | | Special targeting system for viral vectors |
| 2740/14071 | | Demonstrated <u>in vivo</u> effect | 2740/16051 | | Methods of production or purification of viral material |
| 2740/14088 | | For redistribution | 2740/16052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2740/15011 | | Lentivirus, not HIV, e.g. FIV, SIV | 2740/16061 | | Methods of inactivation or attenuation |
| 2740/15021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2740/16062 | | by genetic engineering |
| 2740/15022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2740/16063 | | by chemical treatment |
| 2740/15023 | | Virus like particles [VLP] | 2740/16064 | | by serial passage |
| 2740/15031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2740/16071 | | Demonstrated <u>in vivo</u> effect |
| 2740/15032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2740/16088 | | For redistribution |
| 2740/15033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2740/16111 | | concerning HIV env |
| 2740/15034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2740/16122 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2740/15041 | | Use of virus, viral particle or viral elements as a vector | 2740/16134 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/15042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2740/16171 | | Demonstrated <u>in vivo</u> effect |
| | | | 2740/16188 | | For redistribution |

| | | | | | |
|----------------|---------|---|------------|---------|---|
| 2740/16211 | | concerning HIV gagpol | 2750/00023 | . . | Virus like particles [VLP] |
| 2740/16222 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2750/00031 | . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2740/16234 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2750/00032 | . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2740/16271 | | Demonstrated <u>in vivo</u> effect | 2750/00033 | . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2740/16288 | | For redistribution | 2750/00034 | . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/16311 | | concerning HIV regulatory proteins | 2750/00041 | . . | Use of virus, viral particle or viral elements as a vector |
| 2740/16322 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2750/00042 | . . . | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2740/16334 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2750/00043 | . . . | viral genome or elements thereof as genetic vector |
| 2740/16371 | | Demonstrated <u>in vivo</u> effect | 2750/00044 | . . . | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/16388 | | For redistribution | 2750/00045 | . . . | Special targeting system for viral vectors |
| 2740/17011 | . . . | Spumavirus, e.g. chimpanzee foamy virus | 2750/00051 | . . | Methods of production or purification of viral material |
| 2740/17021 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2750/00052 | . . . | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2740/17022 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2750/00061 | . . | Methods of inactivation or attenuation |
| 2740/17023 | | Virus like particles [VLP] | 2750/00062 | . . . | by genetic engineering |
| 2740/17031 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2750/00063 | . . . | by chemical treatment |
| 2740/17032 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2750/00064 | . . . | by serial passage |
| 2740/17033 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2750/00071 | . . | Demonstrated <u>in vivo</u> effect |
| 2740/17034 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2750/00088 | . . | For redistribution |
| 2740/17041 | | Use of virus, viral particle or viral elements as a vector | 2750/10011 | . . | Circoviridae |
| 2740/17042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2750/10021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2740/17043 | | viral genome or elements thereof as genetic vector | 2750/10022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2740/17044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2750/10023 | . . . | Virus like particles [VLP] |
| 2740/17045 | | Special targeting system for viral vectors | 2750/10031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2740/17051 | | Methods of production or purification of viral material | 2750/10032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2740/17052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2750/10033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2740/17061 | | Methods of inactivation or attenuation | 2750/10034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2740/17062 | | by genetic engineering | 2750/10041 | . . . | Use of virus, viral particle or viral elements as a vector |
| 2740/17063 | | by chemical treatment | 2750/10042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2740/17064 | | by serial passage | 2750/10043 | | viral genome or elements thereof as genetic vector |
| 2740/17071 | | Demonstrated <u>in vivo</u> effect | 2750/10044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2740/17088 | | For redistribution | 2750/10045 | | Special targeting system for viral vectors |
| 2750/00 | | ssDNA Viruses (not used) | 2750/10051 | . . . | Methods of production or purification of viral material |
| 2750/00011 | . . | ssDNA Viruses | 2750/10052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2750/00021 | . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2750/10061 | . . . | Methods of inactivation or attenuation |
| 2750/00022 | . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | | | |

- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 . . . Demonstrated in vivo effect
- 2750/10088 . . . For redistribution
- 2750/12011 . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 . . . Methods of production or purification of viral material
- 2750/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 by genetic engineering
- 2750/12063 by chemical treatment
- 2750/12064 by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . For redistribution
- 2750/14011 . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 viral genome or elements thereof as genetic vector
- 2750/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 Special targeting system for viral vectors
- 2750/14051 . . . Methods of production or purification of viral material
- 2750/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . Methods of inactivation or attenuation
- 2750/14062 by genetic engineering
- 2750/14063 by chemical treatment
- 2750/14064 by serial passage
- 2750/14071 . . . Demonstrated in vivo effect
- 2750/14088 . . . For redistribution
- 2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 Virus like particles [VLP]
- 2750/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 Use of virus, viral particle or viral elements as a vector
- 2750/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 viral genome or elements thereof as genetic vector
- 2750/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 Special targeting system for viral vectors
- 2750/14151 Methods of production or purification of viral material
- 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 Methods of inactivation or attenuation
- 2750/14162 by genetic engineering
- 2750/14163 by chemical treatment
- 2750/14164 by serial passage
- 2750/14171 Demonstrated in vivo effect
- 2750/14188 For redistribution
- 2750/14211 . . . Erythrovirus, e.g. B19 virus
- 2750/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 Virus like particles [VLP]
- 2750/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2750/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 Use of virus, viral particle or viral elements as a vector
- 2750/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 viral genome or elements thereof as genetic vector
- 2750/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 Special targeting system for viral vectors
- 2750/14251 Methods of production or purification of viral material
- 2750/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 Methods of inactivation or attenuation
- 2750/14262 by genetic engineering
- 2750/14263 by chemical treatment
- 2750/14264 by serial passage
- 2750/14271 Demonstrated in vivo effect
- 2750/14288 For redistribution
- 2750/14311 . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 Virus like particles [VLP]
- 2750/14331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 Use of virus, viral particle or viral elements as a vector
- 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 viral genome or elements thereof as genetic vector
- 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 Special targeting system for viral vectors
- 2750/14351 Methods of production or purification of viral material
- 2750/14352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 Methods of inactivation or attenuation
- 2750/14362 by genetic engineering
- 2750/14363 by chemical treatment
- 2750/14364 by serial passage
- 2750/14371 Demonstrated in vivo effect
- 2750/14388 For redistribution
- 2760/00** **ssRNA Viruses negative-sense (not used)**
- 2760/00011 . ssRNA Viruses negative-sense
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated in vivo effect
- 2760/00088 . . For redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2760/10043 viral genome or elements thereof as genetic vector
- 2760/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 Special targeting system for viral vectors
- 2760/10051 Methods of production or purification of viral material
- 2760/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 Methods of inactivation or attenuation
- 2760/10062 by genetic engineering
- 2760/10063 by chemical treatment
- 2760/10064 by serial passage
- 2760/10071 Demonstrated in vivo effect
- 2760/10088 For redistribution
- 2760/10111 Deltavirus, e.g. hepatitis delta virus
- 2760/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 Virus like particles [VLP]
- 2760/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 Use of virus, viral particle or viral elements as a vector
- 2760/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 viral genome or elements thereof as genetic vector
- 2760/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 Special targeting system for viral vectors
- 2760/10151 Methods of production or purification of viral material
- 2760/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 Methods of inactivation or attenuation
- 2760/10162 by genetic engineering
- 2760/10163 by chemical treatment
- 2760/10164 by serial passage
- 2760/10171 Demonstrated in vivo effect
- 2760/10188 For redistribution
- 2760/12011 Bunyaviridae
- 2760/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 Virus like particles [VLP]
- 2760/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 Use of virus, viral particle or viral elements as a vector
- 2760/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 viral genome or elements thereof as genetic vector
- 2760/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 Special targeting system for viral vectors
- 2760/12051 Methods of production or purification of viral material
- 2760/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 Methods of inactivation or attenuation
- 2760/12062 by genetic engineering
- 2760/12063 by chemical treatment
- 2760/12064 by serial passage
- 2760/12071 Demonstrated in vivo effect
- 2760/12088 For redistribution
- 2760/12111 Hantavirus, e.g. Hantaan virus
- 2760/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 Virus like particles [VLP]
- 2760/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 Use of virus, viral particle or viral elements as a vector
- 2760/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 viral genome or elements thereof as genetic vector
- 2760/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 Special targeting system for viral vectors
- 2760/12151 Methods of production or purification of viral material
- 2760/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 Methods of inactivation or attenuation
- 2760/12162 by genetic engineering
- 2760/12163 by chemical treatment

- 2760/12164 by serial passage
- 2760/12171 Demonstrated in vivo effect
- 2760/12188 For redistribution
- 2760/12211 Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 Virus like particles [VLP]
- 2760/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 Use of virus, viral particle or viral elements as a vector
- 2760/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 viral genome or elements thereof as genetic vector
- 2760/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 Special targeting system for viral vectors
- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated in vivo effect
- 2760/12288 For redistribution
- 2760/14011 Filoviridae
- 2760/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 Virus like particles [VLP]
- 2760/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 Use of virus, viral particle or viral elements as a vector
- 2760/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 viral genome or elements thereof as genetic vector
- 2760/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 Special targeting system for viral vectors
- 2760/14051 Methods of production or purification of viral material
- 2760/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 Methods of inactivation or attenuation
- 2760/14062 by genetic engineering
- 2760/14063 by chemical treatment
- 2760/14064 by serial passage
- 2760/14071 Demonstrated in vivo effect
- 2760/14088 For redistribution
- 2760/14111 Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 For redistribution
- 2760/14211 Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated *in vivo* effect
- 2760/14288 For redistribution
- 2760/16011 . . . Orthomyxoviridae
- 2760/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 Virus like particles [VLP]
- 2760/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 Use of virus, viral particle or viral elements as a vector
- 2760/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 viral genome or elements thereof as genetic vector
- 2760/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 Special targeting system for viral vectors
- 2760/16051 Methods of production or purification of viral material
- 2760/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 Methods of inactivation or attenuation
- 2760/16062 by genetic engineering
- 2760/16063 by chemical treatment
- 2760/16064 by serial passage
- 2760/16071 Demonstrated *in vivo* effect
- 2760/16088 For redistribution
- 2760/16111 Influenzavirus A, i.e. influenza A virus
- 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 Virus like particles [VLP]
- 2760/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 Use of virus, viral particle or viral elements as a vector
- 2760/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 viral genome or elements thereof as genetic vector
- 2760/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 Special targeting system for viral vectors
- 2760/16151 Methods of production or purification of viral material
- 2760/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 Methods of inactivation or attenuation
- 2760/16162 by genetic engineering
- 2760/16163 by chemical treatment
- 2760/16164 by serial passage
- 2760/16171 Demonstrated *in vivo* effect
- 2760/16188 For redistribution
- 2760/16211 Influenzavirus B, i.e. influenza B virus
- 2760/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 Virus like particles [VLP]
- 2760/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 Use of virus, viral particle or viral elements as a vector
- 2760/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 viral genome or elements thereof as genetic vector

| | | | | | |
|------------|-----------|---|------------|-----------|---|
| 2760/16244 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2760/18033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2760/16245 | | Special targeting system for viral vectors | 2760/18034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2760/16251 | | Methods of production or purification of viral material | 2760/18041 | . . . | Use of virus, viral particle or viral elements as a vector |
| 2760/16252 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2760/18042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2760/16261 | | Methods of inactivation or attenuation | 2760/18043 | | viral genome or elements thereof as genetic vector |
| 2760/16262 | | by genetic engineering | 2760/18044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2760/16263 | | by chemical treatment | 2760/18045 | | Special targeting system for viral vectors |
| 2760/16264 | | by serial passage | 2760/18051 | . . . | Methods of production or purification of viral material |
| 2760/16271 | | Demonstrated <u>in vivo</u> effect | 2760/18052 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2760/16288 | | For redistribution | 2760/18061 | . . . | Methods of inactivation or attenuation |
| 2760/16311 | . . . | Influenzavirus C, i.e. influenza C virus | 2760/18062 | | by genetic engineering |
| 2760/16321 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2760/18063 | | by chemical treatment |
| 2760/16322 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2760/18064 | | by serial passage |
| 2760/16323 | | Virus like particles [VLP] | 2760/18071 | . . . | Demonstrated <u>in vivo</u> effect |
| 2760/16331 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2760/18088 | . . . | For redistribution |
| 2760/16332 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2760/18111 | . . . | Avulavirus, e.g. Newcastle disease virus |
| 2760/16333 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2760/18121 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2760/16334 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2760/18122 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2760/16341 | | Use of virus, viral particle or viral elements as a vector | 2760/18123 | | Virus like particles [VLP] |
| 2760/16342 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2760/18131 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2760/16343 | | viral genome or elements thereof as genetic vector | 2760/18132 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2760/16344 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2760/18133 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2760/16345 | | Special targeting system for viral vectors | 2760/18134 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2760/16351 | | Methods of production or purification of viral material | 2760/18141 | | Use of virus, viral particle or viral elements as a vector |
| 2760/16352 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2760/18142 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2760/16361 | | Methods of inactivation or attenuation | 2760/18143 | | viral genome or elements thereof as genetic vector |
| 2760/16362 | | by genetic engineering | 2760/18144 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2760/16363 | | by chemical treatment | 2760/18145 | | Special targeting system for viral vectors |
| 2760/16364 | | by serial passage | 2760/18151 | | Methods of production or purification of viral material |
| 2760/16371 | | Demonstrated <u>in vivo</u> effect | 2760/18152 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2760/16388 | | For redistribution | 2760/18161 | | Methods of inactivation or attenuation |
| 2760/18011 | . . . | Paramyxoviridae | 2760/18162 | | by genetic engineering |
| 2760/18021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2760/18163 | | by chemical treatment |
| 2760/18022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2760/18164 | | by serial passage |
| 2760/18023 | . . . | Virus like particles [VLP] | 2760/18171 | | Demonstrated <u>in vivo</u> effect |
| 2760/18031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | | | |
| 2760/18032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | | | |

- 2760/18188 For redistribution
- 2760/18211 . . . Henipavirus, e.g. hendra virus
- 2760/18221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 Virus like particles [VLP]
- 2760/18231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 Use of virus, viral particle or viral elements as a vector
- 2760/18242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 viral genome or elements thereof as genetic vector
- 2760/18244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 Special targeting system for viral vectors
- 2760/18251 Methods of production or purification of viral material
- 2760/18252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 Methods of inactivation or attenuation
- 2760/18262 by genetic engineering
- 2760/18263 by chemical treatment
- 2760/18264 by serial passage
- 2760/18271 Demonstrated in vivo effect
- 2760/18288 For redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 Virus like particles [VLP]
- 2760/18331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 Use of virus, viral particle or viral elements as a vector
- 2760/18342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 viral genome or elements thereof as genetic vector
- 2760/18344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 Special targeting system for viral vectors
- 2760/18351 Methods of production or purification of viral material
- 2760/18352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 Methods of inactivation or attenuation
- 2760/18362 by genetic engineering
- 2760/18363 by chemical treatment
- 2760/18364 by serial passage
- 2760/18371 Demonstrated in vivo effect
- 2760/18388 For redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 Virus like particles [VLP]
- 2760/18431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated in vivo effect
- 2760/18488 For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated in vivo effect
- 2760/18588 For redistribution
- 2760/18611 Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering
- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 For redistribution
- 2760/18711 Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector
- 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 viral genome or elements thereof as genetic vector
- 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 Special targeting system for viral vectors
- 2760/18751 Methods of production or purification of viral material
- 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 Methods of inactivation or attenuation
- 2760/18762 by genetic engineering
- 2760/18763 by chemical treatment
- 2760/18764 by serial passage
- 2760/18771 Demonstrated in vivo effect
- 2760/18788 For redistribution
- 2760/18811 Sendai virus
- 2760/18821 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 Virus like particles [VLP]
- 2760/18831 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 Use of virus, viral particle or viral elements as a vector
- 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

| | | | | | |
|------------|-----------|---|------------|-----------|---|
| 2760/18843 | | viral genome or elements thereof as genetic vector | 2760/20133 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2760/18845 | | Special targeting system for viral vectors | 2760/20134 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2760/18851 | | Methods of production or purification of viral material | 2760/20141 | | Use of virus, viral particle or viral elements as a vector |
| 2760/18852 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2760/20142 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2760/18861 | | Methods of inactivation or attenuation | 2760/20143 | | viral genome or elements thereof as genetic vector |
| 2760/18862 | | by genetic engineering | 2760/20144 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2760/18863 | | by chemical treatment | 2760/20145 | | Special targeting system for viral vectors |
| 2760/18864 | | by serial passage | 2760/20151 | | Methods of production or purification of viral material |
| 2760/18871 | | Demonstrated <u>in vivo</u> effect | 2760/20152 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2760/18888 | | For redistribution | 2760/20161 | | Methods of inactivation or attenuation |
| 2760/20011 | . . | Rhabdoviridae | 2760/20162 | | by genetic engineering |
| 2760/20021 | . . . | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2760/20163 | | by chemical treatment |
| 2760/20022 | . . . | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2760/20164 | | by serial passage |
| 2760/20023 | . . . | Virus like particles [VLP] | 2760/20171 | | Demonstrated <u>in vivo</u> effect |
| 2760/20031 | . . . | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2760/20188 | | For redistribution |
| 2760/20032 | . . . | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2760/20211 | . . . | Vesiculovirus, e.g. vesicular stomatitis Indiana virus |
| 2760/20033 | . . . | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2760/20221 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2760/20034 | . . . | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2760/20222 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2760/20041 | . . . | Use of virus, viral particle or viral elements as a vector | 2760/20223 | | Virus like particles [VLP] |
| 2760/20042 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2760/20231 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2760/20043 | | viral genome or elements thereof as genetic vector | 2760/20232 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2760/20044 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2760/20233 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2760/20045 | | Special targeting system for viral vectors | 2760/20234 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2760/20051 | . . . | Methods of production or purification of viral material | 2760/20241 | | Use of virus, viral particle or viral elements as a vector |
| 2760/20052 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2760/20242 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2760/20061 | . . . | Methods of inactivation or attenuation | 2760/20243 | | viral genome or elements thereof as genetic vector |
| 2760/20062 | | by genetic engineering | 2760/20244 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2760/20063 | | by chemical treatment | 2760/20245 | | Special targeting system for viral vectors |
| 2760/20064 | | by serial passage | 2760/20251 | | Methods of production or purification of viral material |
| 2760/20071 | . . . | Demonstrated <u>in vivo</u> effect | 2760/20252 | | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2760/20088 | . . . | For redistribution | 2760/20261 | | Methods of inactivation or attenuation |
| 2760/20111 | . . . | Lyssavirus, e.g. rabies virus | 2760/20262 | | by genetic engineering |
| 2760/20121 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2760/20263 | | by chemical treatment |
| 2760/20122 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2760/20264 | | by serial passage |
| 2760/20123 | | Virus like particles [VLP] | | | |
| 2760/20131 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | | | |
| 2760/20132 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | | | |

| | | | |
|----------------|---|------------|---|
| 2760/20271 | Demonstrated <u>in vivo</u> effect | 2770/10044 | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2760/20288 | For redistribution | 2770/10045 | Special targeting system for viral vectors |
| 2770/00 | ssRNA Viruses positive-sense (not used) | 2770/10051 | Methods of production or purification of viral material |
| 2770/00011 | . ssRNA Viruses positive-sense | 2770/10052 | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2770/00021 | . . Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2770/10061 | Methods of inactivation or attenuation |
| 2770/00022 | . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2770/10062 | by genetic engineering |
| 2770/00023 | . . Virus like particles [VLP] | 2770/10063 | by chemical treatment |
| 2770/00031 | . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2770/10064 | by serial passage |
| 2770/00032 | . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2770/10071 | Demonstrated <u>in vivo</u> effect |
| 2770/00033 | . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2770/10088 | For redistribution |
| 2770/00034 | . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2770/12011 | Astroviridae |
| 2770/00041 | . . Use of virus, viral particle or viral elements as a vector | 2770/12021 | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2770/00042 | . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2770/12022 | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2770/00043 | . . . viral genome or elements thereof as genetic vector | 2770/12023 | Virus like particles [VLP] |
| 2770/00044 | . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2770/12031 | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| 2770/00045 | . . . Special targeting system for viral vectors | 2770/12032 | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| 2770/00051 | . . . Methods of production or purification of viral material | 2770/12033 | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory |
| 2770/00052 | . . . relating to complementing cells and packaging systems for producing virus or viral particles | 2770/12034 | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein |
| 2770/00061 | . . . Methods of inactivation or attenuation | 2770/12041 | Use of virus, viral particle or viral elements as a vector |
| 2770/00062 | . . . by genetic engineering | 2770/12042 | virus or viral particle as vehicle, e.g. encapsulating small organic molecule |
| 2770/00063 | . . . by chemical treatment | 2770/12043 | viral genome or elements thereof as genetic vector |
| 2770/00064 | . . . by serial passage | 2770/12044 | Chimeric viral vector comprising heterologous viral elements for production of another viral vector |
| 2770/00071 | . . . Demonstrated <u>in vivo</u> effect | 2770/12045 | Special targeting system for viral vectors |
| 2770/00088 | . . . For redistribution | 2770/12051 | Methods of production or purification of viral material |
| 2770/10011 | . . . Arteriviridae | 2770/12052 | relating to complementing cells and packaging systems for producing virus or viral particles |
| 2770/10021 | . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2770/12061 | Methods of inactivation or attenuation |
| 2770/10022 | . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2770/12062 | by genetic engineering |
| 2770/10023 | . . . Virus like particles [VLP] | 2770/12063 | by chemical treatment |
| 2770/10031 | . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2770/12064 | by serial passage |
| 2770/10032 | . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2770/12071 | Demonstrated <u>in vivo</u> effect |
| 2770/10033 | . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2770/12088 | For redistribution |
| 2770/10034 | . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2770/14011 | Bromoviridae |
| 2770/10041 | . . . Use of virus, viral particle or viral elements as a vector | 2770/14021 | Viruses as such, e.g. new isolates, mutants or their genomic sequences |
| 2770/10042 | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2770/14022 | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes |
| 2770/10043 | viral genome or elements thereof as genetic vector | 2770/14023 | Virus like particles [VLP] |
| | | 2770/14031 | Uses of virus other than therapeutic or vaccine, e.g. disinfectant |
| | | 2770/14032 | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |

- 2770/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 . . . Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 . . . Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 . . . Demonstrated in vivo effect
- 2770/14088 . . . For redistribution
- 2770/16011 . . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 . . . Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 . . . Demonstrated in vivo effect
- 2770/16088 . . . For redistribution
- 2770/18011 . . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 . . . Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 . . . Demonstrated in vivo effect
- 2770/18088 . . . For redistribution
- 2770/20011 . . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector

- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 Demonstrated in vivo effect
- 2770/20088 For redistribution
- 2770/22011 Dicistroviridae
- 2770/22021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 Virus like particles [VLP]
- 2770/22031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 Demonstrated in vivo effect
- 2770/22088 For redistribution
- 2770/24011 Flaviviridae
- 2770/24021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 Virus like particles [VLP]
- 2770/24031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment
- 2770/24064 by serial passage
- 2770/24071 Demonstrated in vivo effect
- 2770/24088 For redistribution
- 2770/24111 Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect

- 2770/24188 For redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector
- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated in vivo effect
- 2770/24288 For redistribution
- 2770/24311 . . . Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector
- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated in vivo effect
- 2770/24388 For redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 . . . Virus like particles [VLP]
- 2770/26031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 . . . Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 . . . Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . For redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . For redistribution
- 2770/28111 . . . Hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated in vivo effect
- 2770/28188 For redistribution
- 2770/30011 Nodaviridae
- 2770/30021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 Virus like particles [VLP]
- 2770/30031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector
- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 Demonstrated in vivo effect
- 2770/30088 For redistribution
- 2770/32011 Picornaviridae
- 2770/32021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 Virus like particles [VLP]
- 2770/32031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector

- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 Demonstrated in vivo effect
- 2770/32088 For redistribution
- 2770/32111 Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated in vivo effect
- 2770/32188 For redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated in vivo effect
- 2770/32288 For redistribution
- 2770/32311 Enterovirus
- 2770/32321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 Virus like particles [VLP]
- 2770/32331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 Use of virus, viral particle or viral elements as a vector
- 2770/32342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 viral genome or elements thereof as genetic vector
- 2770/32344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 Special targeting system for viral vectors
- 2770/32351 Methods of production or purification of viral material
- 2770/32352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 Methods of inactivation or attenuation
- 2770/32362 by genetic engineering
- 2770/32363 by chemical treatment
- 2770/32364 by serial passage
- 2770/32371 Demonstrated in vivo effect

- 2770/32388 For redistribution
- 2770/32411 . . . Hepatovirus, i.e. hepatitis A virus
- 2770/32421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 Virus like particles [VLP]
- 2770/32431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 Use of virus, viral particle or viral elements as a vector
- 2770/32442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 viral genome or elements thereof as genetic vector
- 2770/32444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 Special targeting system for viral vectors
- 2770/32451 Methods of production or purification of viral material
- 2770/32452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 Methods of inactivation or attenuation
- 2770/32462 by genetic engineering
- 2770/32463 by chemical treatment
- 2770/32464 by serial passage
- 2770/32471 Demonstrated in vivo effect
- 2770/32488 For redistribution
- 2770/32511 . . . Parechovirus, e.g. human parechovirus
- 2770/32521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 Virus like particles [VLP]
- 2770/32531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 Use of virus, viral particle or viral elements as a vector
- 2770/32542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 viral genome or elements thereof as genetic vector
- 2770/32544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32545 Special targeting system for viral vectors
- 2770/32551 Methods of production or purification of viral material
- 2770/32552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32561 Methods of inactivation or attenuation
- 2770/32562 by genetic engineering
- 2770/32563 by chemical treatment
- 2770/32564 by serial passage
- 2770/32571 Demonstrated in vivo effect
- 2770/32588 For redistribution
- 2770/32611 . . . Poliovirus
- 2770/32621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32623 Virus like particles [VLP]
- 2770/32631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 Use of virus, viral particle or viral elements as a vector
- 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 viral genome or elements thereof as genetic vector
- 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 Special targeting system for viral vectors
- 2770/32651 Methods of production or purification of viral material
- 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 Methods of inactivation or attenuation
- 2770/32662 by genetic engineering
- 2770/32663 by chemical treatment
- 2770/32664 by serial passage
- 2770/32671 Demonstrated in vivo effect
- 2770/32688 For redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 Virus like particles [VLP]
- 2770/32731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/32733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 Use of virus, viral particle or viral elements as a vector
- 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 viral genome or elements thereof as genetic vector
- 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 Special targeting system for viral vectors
- 2770/32751 Methods of production or purification of viral material
- 2770/32752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 Methods of inactivation or attenuation
- 2770/32762 by genetic engineering
- 2770/32763 by chemical treatment
- 2770/32764 by serial passage
- 2770/32771 Demonstrated in vivo effect
- 2770/32788 For redistribution
- 2770/34011 . . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 viral genome or elements thereof as genetic vector
- 2770/34044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 by genetic engineering
- 2770/34063 by chemical treatment
- 2770/34064 by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . For redistribution
- 2770/36011 . . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector
- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . For redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector

- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 For redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated in vivo effect
- 2770/36288 For redistribution
- 2770/38011 . . . Tombusviridae
- 2770/38021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . Virus like particles [VLP]
- 2770/38031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 . . . Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment
- 2770/38064 by serial passage
- 2770/38071 . . . Demonstrated in vivo effect
- 2770/38088 . . . For redistribution
- 2770/40011 . . . Tymoviridae
- 2770/40021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . Virus like particles [VLP]
- 2770/40031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 . . . Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 . . . Demonstrated in vivo effect

- 2770/40088 . . . For redistribution
- 2780/00** **Naked RNA Viruses (not used)**
- 2780/00011 . Naked RNA Viruses
- 2780/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . Virus like particles [VLP]
- 2780/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . For redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 viral genome or elements thereof as genetic vector
- 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 Special targeting system for viral vectors
- 2780/10051 Methods of production or purification of viral material
- 2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 Methods of inactivation or attenuation
- 2780/10062 by genetic engineering
- 2780/10063 by chemical treatment
- 2780/10064 by serial passage
- 2780/10071 Demonstrated in vivo effect
- 2780/10088 For redistribution
- 2790/00** **Viroids and subviral agents (not used)**
- 2790/00011 . Viroids and subviral agents
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]
- 2790/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 . . . viral genome or elements thereof as genetic vector
- 2790/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 . . . Special targeting system for viral vectors
- 2790/00051 . . Methods of production or purification of viral material
- 2790/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . Methods of inactivation or attenuation
- 2790/00062 . . . by genetic engineering
- 2790/00063 . . . by chemical treatment
- 2790/00064 . . . by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . For redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 by genetic engineering
- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 . . . Demonstrated in vivo effect
- 2790/10088 . . . For redistribution
- 2790/12011 . . Satellite viruses
- 2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 . . . Virus like particles [VLP]
- 2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 . . . Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 . . . Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment
- 2790/12064 by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . For redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 viral genome or elements thereof as genetic vector
- 2790/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 by genetic engineering
- 2790/14063 by chemical treatment
- 2790/14064 by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . For redistribution
- 2792/00** **Archaeobacteria viruses (not used)**
- 2792/00011 . Archaeobacteria viruses
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]
- 2792/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2792/00043 . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 . . . Special targeting system for viral vectors
- 2792/00051 . . Methods of production or purification of viral material
- 2792/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . Methods of inactivation or attenuation
- 2792/00062 . . . by genetic engineering
- 2792/00063 . . . by chemical treatment
- 2792/00064 . . . by serial passage
- 2792/00071 . . Demonstrated in vivo effect
- 2792/00088 . . For redistribution
- 2792/10011 . . Fuselloviridae
- 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . Virus like particles [VLP]
- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 viral genome or elements thereof as genetic vector
- 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 by genetic engineering
- 2792/10063 by chemical treatment
- 2792/10064 by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . For redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 viral genome or elements thereof as genetic vector
- 2792/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . For redistribution
- 2795/00 Bacteriophages (not used)**
- 2795/00011 . Bacteriophages
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering

- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . For redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 viral genome or elements thereof as genetic vector
- 2795/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 Special targeting system for viral vectors
- 2795/10051 . . . Methods of production or purification of viral material
- 2795/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 . . . Methods of inactivation or attenuation
- 2795/10062 by genetic engineering
- 2795/10063 by chemical treatment
- 2795/10064 by serial passage
- 2795/10071 . . . Demonstrated in vivo effect
- 2795/10088 . . . For redistribution
- 2795/10111 . . . Myoviridae
- 2795/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 Virus like particles [VLP]
- 2795/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 Use of virus, viral particle or viral elements as a vector
- 2795/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 viral genome or elements thereof as genetic vector
- 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 Special targeting system for viral vectors
- 2795/10151 Methods of production or purification of viral material
- 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 Methods of inactivation or attenuation
- 2795/10162 by genetic engineering
- 2795/10163 by chemical treatment
- 2795/10164 by serial passage
- 2795/10171 Demonstrated in vivo effect
- 2795/10188 For redistribution
- 2795/10211 . . . Podoviridae
- 2795/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 Virus like particles [VLP]
- 2795/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 Use of virus, viral particle or viral elements as a vector
- 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 viral genome or elements thereof as genetic vector
- 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 Special targeting system for viral vectors
- 2795/10251 Methods of production or purification of viral material
- 2795/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 Methods of inactivation or attenuation
- 2795/10262 by genetic engineering
- 2795/10263 by chemical treatment
- 2795/10264 by serial passage
- 2795/10271 Demonstrated in vivo effect
- 2795/10288 For redistribution
- 2795/10311 . . . Siphoviridae
- 2795/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 Virus like particles [VLP]
- 2795/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 Use of virus, viral particle or viral elements as a vector
- 2795/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 viral genome or elements thereof as genetic vector
- 2795/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 Special targeting system for viral vectors
- 2795/10351 Methods of production or purification of viral material
- 2795/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 Methods of inactivation or attenuation
- 2795/10362 by genetic engineering
- 2795/10363 by chemical treatment
- 2795/10364 by serial passage
- 2795/10371 Demonstrated in vivo effect
- 2795/10388 For redistribution
- 2795/12011 . . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 viral genome or elements thereof as genetic vector
- 2795/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 Special targeting system for viral vectors
- 2795/12051 Methods of production or purification of viral material
- 2795/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 Methods of inactivation or attenuation
- 2795/12062 by genetic engineering
- 2795/12063 by chemical treatment
- 2795/12064 by serial passage
- 2795/12071 Demonstrated in vivo effect
- 2795/12088 For redistribution
- 2795/14011 . . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 viral genome or elements thereof as genetic vector
- 2795/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 Special targeting system for viral vectors
- 2795/14051 Methods of production or purification of viral material
- 2795/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 Methods of inactivation or attenuation
- 2795/14062 by genetic engineering
- 2795/14063 by chemical treatment
- 2795/14064 by serial passage
- 2795/14071 Demonstrated in vivo effect
- 2795/14088 For redistribution
- 2795/14111 Inoviridae
- 2795/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 Virus like particles [VLP]
- 2795/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 Use of virus, viral particle or viral elements as a vector
- 2795/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 viral genome or elements thereof as genetic vector

- 2795/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 Special targeting system for viral vectors
- 2795/14151 Methods of production or purification of viral material
- 2795/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 Methods of inactivation or attenuation
- 2795/14162 by genetic engineering
- 2795/14163 by chemical treatment
- 2795/14164 by serial passage
- 2795/14171 Demonstrated *in vivo* effect
- 2795/14188 For redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 Virus like particles [VLP]
- 2795/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 Use of virus, viral particle or viral elements as a vector
- 2795/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 viral genome or elements thereof as genetic vector
- 2795/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 Special targeting system for viral vectors
- 2795/14251 Methods of production or purification of viral material
- 2795/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 Methods of inactivation or attenuation
- 2795/14262 by genetic engineering
- 2795/14263 by chemical treatment
- 2795/14264 by serial passage
- 2795/14271 Demonstrated *in vivo* effect
- 2795/14288 For redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 viral genome or elements thereof as genetic vector
- 2795/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 Special targeting system for viral vectors
- 2795/16051 . . . Methods of production or purification of viral material
- 2795/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 . . . Methods of inactivation or attenuation
- 2795/16062 by genetic engineering
- 2795/16063 by chemical treatment
- 2795/16064 by serial passage
- 2795/16071 . . . Demonstrated *in vivo* effect
- 2795/16088 . . . For redistribution
- 2795/18011 . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . Virus like particles [VLP]
- 2795/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 viral genome or elements thereof as genetic vector
- 2795/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 Special targeting system for viral vectors
- 2795/18051 . . . Methods of production or purification of viral material
- 2795/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 . . . Methods of inactivation or attenuation
- 2795/18062 by genetic engineering
- 2795/18063 by chemical treatment
- 2795/18064 by serial passage
- 2795/18071 . . . Demonstrated *in vivo* effect

| | | | | | |
|----------------|---|---|----------------|--|---|
| 2795/18088 | . . . | For redistribution | 2800/103 | . . | for invertebrates |
| 2795/18111 | . . . | Leviviridae | 2800/105 | . . . | for insects |
| 2795/18121 | | Viruses as such, e.g. new isolates, mutants or their genomic sequences | 2800/106 | . . | for vertebrates |
| 2795/18122 | | New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes | 2800/107 | . . . | for mammalian |
| 2795/18123 | | Virus like particles [VLP] | 2800/108 | . . | episomal vectors |
| 2795/18131 | | Uses of virus other than therapeutic or vaccine, e.g. disinfectant | 2800/20 | . . | Pseudochromosomes, minichromosomes |
| 2795/18132 | | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent | 2800/202 | . . | of bacteriophage origin |
| 2795/18133 | | Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory | 2800/204 | . . | of bacterial origin, e.g. BAC |
| 2795/18134 | | Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein | 2800/206 | . . | of yeast origin, e.g. YAC, 2u |
| 2795/18141 | | Use of virus, viral particle or viral elements as a vector | 2800/208 | . . | of mammalian origin, e.g. minichromosome |
| 2795/18142 | | virus or viral particle as vehicle, e.g. encapsulating small organic molecule | 2800/22 | . . | Vectors comprising a coding region that has been codon optimised for expression in a respective host |
| 2795/18143 | | viral genome or elements thereof as genetic vector | 2800/24 | . . | Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication |
| 2795/18144 | | Chimeric viral vector comprising heterologous viral elements for production of another viral vector | 2800/30 | . . | Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT |
| 2795/18145 | | Special targeting system for viral vectors | 2800/40 | . . | Systems of functionally co-operating vectors |
| 2795/18151 | | Methods of production or purification of viral material | 2800/50 | . . | Vectors for producing vectors |
| 2795/18152 | | relating to complementing cells and packaging systems for producing virus or viral particles | 2800/60 | . . | Vectors containing traps for, e.g. exons, promoters |
| 2795/18161 | | Methods of inactivation or attenuation | 2800/70 | . . | Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites |
| 2795/18162 | | by genetic engineering | 2800/80 | . . | Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites |
| 2795/18163 | | by chemical treatment | 2800/90 | . . | Vectors containing a transposable element |
| 2795/18164 | | by serial passage | 2800/95 | . . | Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers |
| 2795/18171 | | Demonstrated <i>in vivo</i> effect | | | |
| 2795/18188 | | For redistribution | | | |
| 2799/00 | Uses of viruses | | | | |
| | <u>WARNING</u> | | | | |
| | From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00 - C12N 2795/00 | | | | |
| 2799/02 | . . | as vector | 2810/00 | Vectors comprising a targeting moiety | |
| 2799/021 | . . | for the expression of a heterologous nucleic acid | 2810/10 | . . | Vectors comprising a non-peptidic targeting moiety |
| 2799/022 | . . . | where the vector is derived from an adenovirus | 2810/40 | . . | Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source |
| 2799/023 | . . . | where the vector is derived from a poxvirus | 2810/405 | . . | Vectors comprising RGD peptide |
| 2799/025 | . . . | where the vector is derived from a parvovirus | 2810/50 | . . | Vectors comprising as targeting moiety peptide derived from defined protein |
| 2799/026 | . . . | where the vector is derived from a baculovirus | 2810/55 | . . | from bacteria |
| 2799/027 | . . . | where the vector is derived from a retrovirus | 2810/60 | . . | from viruses |
| 2799/028 | . . . | where the vector is derived from a herpesvirus | 2810/6009 | . . . | dsDNA viruses |
| 2799/04 | . . | <i>in vivo</i> | 2810/6018 | | Adenoviridae |
| 2799/06 | . . | <i>in vitro</i> | 2810/6027 | . . . | ssDNA viruses |
| 2800/00 | Nucleic acids vectors | | | | |
| 2800/10 | . . | Plasmid DNA | 2810/6036 | . . . | DNA rev transcr viruses |
| 2800/101 | . . | for bacteria | 2810/6045 | . . . | RNA rev transcr viruses |
| 2800/102 | . . | for yeast | 2810/6054 | | Retroviridae |
| | | | 2810/6063 | . . . | ds RNA viruses |
| | | | 2810/6072 | . . . | negative strand RNA viruses |
| | | | 2810/6081 | | rhabdoviridae, e.g. VSV |
| | | | 2810/609 | . . . | positive strand RNA viruses |
| | | | 2810/65 | . . | from plants |
| | | | 2810/70 | . . | from fungi |
| | | | 2810/75 | . . | from invertebrates |
| | | | 2810/80 | . . | from vertebrates |
| | | | 2810/85 | . . . | mammalian |
| | | | 2810/851 | | from growth factors; from growth regulators |
| | | | 2810/852 | | from cytokines; from lymphokines; from interferons |
| | | | 2810/853 | | from tumor necrosis factor, TNF |
| | | | 2810/854 | | from hormones |
| | | | 2810/855 | | from receptors; from cell surface antigens; from cell surface determinants |
| | | | 2810/856 | | from integrins |
| | | | 2810/857 | | from blood coagulation or fibrinolysis factors |
| | | | 2810/858 | | from apolipoproteins |
| | | | 2810/859 | | from immunoglobulins |

| | | | |
|----------------|---|----------------|--|
| 2810/90 | . . . avian | 2830/80 | . from vertebrates |
| 2820/00 | Vectors comprising a special origin of replication system | 2830/85 | . . mammalian |
| 2820/002 | . inducible or controllable | 2830/90 | . . avian |
| 2820/005 | . cell-cycle regulated | 2840/00 | Vectors comprising a special translation-regulating system |
| 2820/007 | . tissue or cell-specific | 2840/002 | . controllable or inducible |
| 2820/10 | . multiple origins of replication | 2840/005 | . cell cycle specific |
| 2820/55 | . from bacteria | 2840/007 | . cell or tissue specific |
| 2820/60 | . from viruses | 2840/10 | . regulates levels of translation |
| 2820/65 | . from plants | 2840/102 | . . inhibiting translation |
| 2820/70 | . from fungi | 2840/105 | . . enhancing translation |
| 2820/702 | . . yeast | 2840/107 | . . inhibiting translational read-through |
| 2820/704 | . . . S. cerevisiae | 2840/20 | . translation of more than one cistron |
| 2820/706 | . . . S. pombe | 2840/203 | . . having an IRES |
| 2820/708 | . . . C. albicans | 2840/206 | . . . having multiple IRES |
| 2820/75 | . from invertebrates | 2840/44 | . being a specific part of the splice mechanism, e.g. donor, acceptor |
| 2820/80 | . from vertebrates | 2840/445 | . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing |
| 2820/85 | . . mammalian | 2840/50 | . utilisation of non-ATG initiation codon |
| 2820/90 | . . avian | | |
| 2830/00 | Vector systems having a special element relevant for transcription | | NOTE |
| 2830/001 | . controllable enhancer/promoter combination | | This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here |
| 2830/002 | . . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor | | |
| 2830/003 | . . . tet inducible | 2840/55 | . from bacteria |
| 2830/005 | . . repressible enhancer/promoter combination, e.g. KRAB | 2840/60 | . from viruses |
| 2830/006 | . . . tet repressible | 2840/65 | . from plants |
| 2830/007 | . cell cycle specific enhancer/promoter combination | 2840/70 | . from fungi |
| 2830/008 | . cell type or tissue specific enhancer/promoter combination | 2840/702 | . . yeast |
| 2830/15 | . chimeric enhancer/promoter combination | 2840/704 | . . . S. cerevisiae |
| 2830/20 | . transcription of more than one cistron | 2840/706 | . . . S. pombe |
| 2830/205 | . . bidirectional | 2840/708 | . . . C. albicans |
| 2830/30 | . being an enhancer not forming part of the promoter region | 2840/75 | . from invertebrates |
| 2830/32 | . being an silencer not forming part of the promoter region | 2840/80 | . from vertebrates |
| 2830/34 | . being a transcription initiation element | 2840/85 | . . mammalian |
| 2830/36 | . being a transcription termination element | 2840/90 | . . avian |
| 2830/38 | . being a stuffer | 2999/00 | Further aspects of viruses or vectors not covered by the C12N 2700/00 or C12N 2800/00 series |
| 2830/40 | . being an insulator | | NOTES |
| 2830/42 | . being an intron or intervening sequence for splicing and/or stability of RNA | | 1. This group is for classification of patent and non-patent literature documents. |
| 2830/46 | . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island | | 2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate. |
| 2830/48 | . regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE | 2999/002 | . Adverse teaching |
| 2830/50 | . regulating RNA stability, not being an intron, e.g. poly A signal | 2999/005 | . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic |
| 2830/52 | . encoding ribozyme for self-inactivation | 2999/007 | . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals |
| 2830/55 | . from bacteria | | |
| 2830/60 | . from viruses | | |
| 2830/65 | . from plants | | |
| 2830/70 | . from fungi | | |
| 2830/702 | . . yeast | | |
| 2830/704 | . . . S. cerevisiae | | |
| 2830/706 | . . . S. pombe | | |
| 2830/708 | . . . C. albicans | | |
| 2830/75 | . from invertebrates | | |